FINAL
PROGRAM

CALBIO summit 2003

SESSIONS

SPEAKERS

EXHIBITS

NETWORK

THE SCIENCE OF SUCCESS:
Thriving in Challenging Times

MARCH 10 & 11, 2003 | SAN DIEGO CONVENTION CENTER

Dear Friends:

Welcome to CALBIOsummit 2003, "The Science of Success – Thriving in Challenging Times." With guidance from our Steering Committee, we have put together a program that focuses on the devices necessary to move our companies forward.

The Program, "The Science of Success – Thriving in Challenging Times" has been designed to address specific topics that are important in moving our companies forward during these difficult times. The conference will open with workshops on Monday, March 10 that will provide an interactive training experience for our employees on specific topics including accounting, intellectual property and human resources. The sessions on Tuesday, March 11 will feature broad ranging discussion of important issues in panels led by key industry leaders. Monday evening will feature BIOCOM's first Annual Dinner, "Celebration of Life". Our keynote speaker Naomi Judd will relate to the life sciences industry from the patient prospective, reminding us of how important our work is. Also, awards will be given to key supporters of the industry and leaders within the industry.

Our Breakfast Plenary Session on Tuesday, March 11 will feature top executives from biotech and pharmaceutical companies offering their insight on the future of alliances. This panel, moderated by Fred Frank, Senior Vice President, of Lehman Brothers, will be one that you won't want to miss. The Lunch Plenary Session will feature Carl Feldbaum, President of the Biotechnology Industry Organization presenting his State of the Industry for 2003 and Shonda Schilling, wife of Arizona Diamondback pitcher Curt Schilling, who will provide her patient's perspective on the life science industry.

This letter cannot begin to convey the excitement we are feeling about the program for CALBIOsummit 2003. We know this will be an important meeting for all of California. Many thanks to our Steering Committee and committee members for their tireless efforts and to our sponsors and exhibitors for their commitment and support of this important program.

Sincerely,

DAVID HALE
President and CEO
CancerVax, Corporation

JOSEPH PANETTA
President
BIOCOM

Chairman
Steering Committee
CALBIOsummit 2003

GOVERNOR GRAY DAVIS

March 10, 2003

Dear Friends,

It is a great pleasure to extend warm greetings to all who have gathered for CALBIOsummit 2003. This eleventh annual event is a wonderful opportunity to bring together life science leaders to share information and address the most pressing issues facing the vitality of their industry.

I salute the organizers, participants, and supporters of CALBIOsummit 2003 for promoting innovation and research not only in the Golden State, but also in the global community. Their ongoing efforts to encourage progress and scientific advancement will help Californians lead happier and healthier lives.

On behalf of the people of the State of California, I extend best wishes for a successful event.

Sincerely,

Gray Davis

GRAY DAVIS

STATE CAPITOL • SACRAMENTO, CALIFORNIA 95814 • (916) 445-2841

DICK MURPHY
MAYOR

GREETINGS

TO

CALBIOSUMMIT 2003 PARTICIPANTS

March 10 - 11, 2003

It is with great pleasure that I welcome you to San Diego. We are honored to again be selected as the host city for your twelfth annual west coast conference and trade show for the life sciences industry.

Most people think of San Diego for its seventy miles of beautiful beaches and world-famous zoo. But we have so much more to experience. You will discover an international city rich in the arts and culture, nationally recognized theaters, the largest concentration of museums west of the Mississippi and a lively downtown with award-winning restaurants, shops and galleries. San Diego is also home to eclectic neighborhoods such as historic Old Town, Hillcrest and Mission Valley. When you mix together the warmth of our people with our beautiful natural environment and attractions such as Sea World, Cabrillo National Monument, Mission Bay Park and Seaport Village on San Diego Bay, you are sure to discover why we are becoming known as "A City Worthy of Our Affection."

Please accept my warm wishes for a productive stay in San Diego. I am sure you will agree that San Diego is truly a city worthy of your affection. And we will happily await your return visit.

Best regards,

DICK MURPHY
Mayor
City of San Diego

CITY ADMINISTRATION BUILDING, 202 C STREET, SAN DIEGO, CALIFORNIA 92101 (619) 236-6330

CALBIO summit 2003

Designed and Produced by **Mentus**, San Diego, CA

CALBIO summit 2003

Schedule

Conference Schedule

Monday, March 10, 2003

12 Noon	– 7:30 pm	Registration
1:30	– 3:00 pm	Workshops
3:00	– 3:30 pm	Break
3:30	– 5:00 pm	Workshops
5:30	– 6:45 pm	Reception in the Exhibit Hall
7:00	– 9:30 pm	Inaugural BIOCOM Annual Dinner

Tuesday, March 11, 2003

7:00	– 3:00 pm	Registration
8:00	– 10:30 am	Opening Plenary Breakfast
10:30	– 11:00 am	Break in Exhibit Hall
10:30	– 4:00 pm	Exhibit Hall Open
11:00	– 12:30 pm	Sessions
12:30	– 2:00 pm	Plenary Lunch
2:00	– 3:30 pm	Sessions
3:30	– 4:00 pm	Break
4:00	– 5:30 pm	Sessions

Special Thanks to our Session Sponsors

Accenture
Avanir Pharmaceuticals
Gary Cary Ware & Freidenrich
Latham & Watkins LLP
Mentus

Special Thanks to our Workshop Sponsors

Atkins + Associates
Deloitte & Touche
Ernst & Young LLP
Morrison & Foerster LLP
VWR International

All events take place at the San Diego Convention Center unless noted otherwise

Workshops

Monday, March 10, 2003 Workshops

Public Relations/Investor Relations

SPONSORED BY ATKINS + ASSOCIATES

ROOM 10

1:30pm - 3:00pm

Befriending the Media: Oh please, please tell me what they want!

Why did a reporter write on animal data but could care less about my positive Phase II data? Should I correct a reporter if they got the information wrong in their story? How do reporters feel about embargoes? Do they really want an exclusive? How technical should I be in my press release...what about my pitch? How can I get a reporter to meet with my CEO? All these questions and more will be addressed in this highly interactive workshop which includes a panel of top tier broadcast, print and radio reporters. Following the panel discussion, workshop participants will break into smaller groups and work with media relations executives on perfecting a pitch. Once the pitch is perfected, participants will have the opportunity to pitch their story to the members of the media. Following the pitch, the media will have the chance to ask follow up questions, schedule an interview OR tell you why they would have no interest.

Moderator: Carin C. Canale, Vice President, Atkins + Associates

Panelists: Lee Bruno, Technology Editor, Red Herring

Rex Dalton, West Coast Correspondent, Nature

Russell Lewis, News Reporter, National Public Radio

Kristen Philipkoski, Biotechnology Reporter, Wired News

Andrew Pollack, Biotechnology Writer, New York Times

3:30pm - 5:00pm

What Wall Street Wants: How to make the long and winding road lead to a pot of gold?

What does a biotechnology company need to do and say in these turbulent markets to not only survive, but thrive? This workshop will be a tough love, guerrilla session facilitated by leaders in the biotechnology financial arena including venture capitalists, investment bankers and members of the buy and sell side. The panel will address a number of items including which investors biotechnology companies should be targeting, how a company can improve its investor mix and how to approach underserved markets – and the panel will also be ready to answer all the hard-hitting questions from corporate communication and investor relations professionals in attendance. Following the panel discussion, the workshop participants will break into smaller groups with a panel member in each group. The panel member will give candid feedback on the elevator pitch of each participant. Workshop participants will also be asked to bring their company presentation on CD and the panel member will give honest, but possibly pain-staking, feedback on the presentation of the brave participant who agreed to show their presentation to the break-out group.

Moderator: David F. Hale, President and CEO, CancerVax Corporation

Panelists: Standish Fleming, Managing Member, Forward Ventures

Fariba Ghodsian, Ph.D., Managing Member and Director of Research, Castle Creek Lifescience Partners LLC

George J. Milstein, Senior Managing Director, Pacific Growth Equities

Facilities

ROOM 7B

1:30pm - 3:00pm, 3:30pm - 5:00pm

The What, When, Where, Why and HOW of Acquiring Space

Facilities for biotechnology companies are second in cost only to those of recruiting and retaining your staff. Facility leases create long-term and often inflexible financial obligations and warrant thorough understanding prior to commitment. But times are changing and landlords are responding to a more competitive market with greater flexibility and creativity in their lease structures. As well, more and more property owners are looking to the biotech market for their assets, many of which were not originally intended to house laboratory functions. This session brings together users, landlords, venture capitalists, lawyers, architects and builders who offer direct and provocative input to the full scope of facility issues.

Moderators: Kennon W. Baldwin, President, McGraw/Baldwin Architects
Brent Jacobs, Senior Vice President, Burnham Real Estate Services
Panelists: Maria C. Walker, CPA, Chief Operating and Financial Officer, Forward Ventures
Magda Marquet, Ph.D., Co-President & Co-CEO, Althea Technologies Inc.
Nick Rinaldi, President, Occupational Services, Inc.
Fred Carmody, President, Biostruct Sources Inc.
James T. Ferguson, Vice President, McGraw/Baldwin Architects
William Rogalla, Vice President of Development, Slough Estates (Invited)

Accounting

SPONSORED BY ERNST & YOUNG LLP

ROOM 8

1:30pm - 3:00pm

What Sarbanes means to Life Sciences Companies: Who's minding my store?

In today's new business environment, you may feel everyone is minding your store, and you would be right. Sure, you've got big brother peeking over your shoulder and a whole host of new individuals who are suddenly interested in your every move. But you can make this new-found attention work for you. How can general counsel help? How will your relationship with your auditor be impacted? What will your Audit Committee need to focus on? Don't sweat it. It is all good! This workshop will provide you with some helpful insights and best practices for dealing with this new environment.

Moderator: Richard Mejia, Jr., Partner and Southern California Director of Life Sciences, Ernst & Young LLP
Panelists: Phil Schneider, former CFO of IDEC Pharmaceuticals Corporation, Audit Committee Chair Gen-Probe, Inc.
Bruce Stump, Partner, Ernst & Young and Southern California Champion on Implementing Sarbanes-Oxley Initiatives

3:30pm - 5:00 pm

Key Issues facing Life Sciences CFO's in 2003:

The landscape of financing for Life Sciences Companies is changing. "Cash is King" in today's market. This workshop will focus on experiences in today's economic environment that CFO's are facing. We will discuss how Partnering and Joint Ventures are strategically formed; how life sciences companies navigate through the stages leading up to commercialization, and creative financing structures in this tough environment.

Moderator: Rich Mejia, Partner and Southern California Director of Life Sciences, Ernst & Young LLP
Panelists: Marty Glick, Executive Vice President and Chief Financial Officer, Theravance, Inc.
Chris Nolet, Partner and Pacific Northwest Director of Life Sciences, Ernst & Young LLP
B. Lynne Parshall, J.D., Executive Vice President and Chief Financial Officer, Isis Pharmaceuticals, Inc.
James D. Watson, Strategic Partnering Services, Burrill and Company

Clinical/Regulatory

SPONSORED BY DELOITTE & TOUCHE

ROOM 7A

1:30pm - 3:00pm

"Begin with the End In Mind" - A New Paradigm for Product Development or Are These Lessons We Should Have Learned Already?

How to develop a winning biotech thoroughbred may require that you start the race at the finish line. This highly-interactive session will explore how, by focusing on the end result, firms can maximize their chances for developmental success. Featured talks will highlight: how design controls rules force the device industry to focus on the end before starting device design; drug firms that use the "Annotated Label" approach to more efficiently drive development requirements; understanding why the Sales folks really can be your friends; the steps you need to take, before you start the development process, to ensure you will garner public and private reimbursement funds.

Moderator: Glen Paul Freiberg, R.A.C., Vice President Regulatory, Quality & Government Affairs, Gen-Probe, Inc.



BIOCOM Annual Dinner

Monday, March 10, 2003
San Diego Convention Center, Ballroom 6C

5:30pm Registration & Cocktail Reception
7:00pm Dinner & Program

Keynote address: Naomi Judd, country artist and motivational speaker

Celebrate the year's achievements in the Life Sciences Industry with San Diego and California life science, research, educational and political leaders, along with a dynamic cross-section of other key industry executives.

Presented by BIOCOM Sponsored by Pfizer La Jolla

Schedule

Panelists: Joyce H. Williams, R.A.C., Vice President, Drug Development, Arena Pharmaceuticals, Inc.
Jo Ellen Slurzberg, Executive Director, Boston Healthcare (invited)
Karen Church, R.A.C., Vice President, Regulatory Affairs, La Jolla Pharmaceutical Company

3:30pm - 5:00pm

"Virtual Product Development" - Secrets to Successful Outsourcing in Biotech Product Development - or Can You Really Trust Anyone Who's Not Family?

The average California biotech employs perhaps 30 people, may have no lab or manufacturing facility, and might truly be in a garage. How do you drive from your garage to the Fortune 500? While outsourcing is not new, it remains a crucial element in the product development war. How to best use the biomedical mercenaries among us will be the aim of this session, which will feature views from a major CRO, an experienced sponsor's view of the do's and don't's of outsourcing, and real examples of winners and where disasters may lie.

Moderator: Bernard D. King, M.D., M.B.A., President and CEO, Macnas Consulting International
Panelists: Tim Krupa, Executive Group Director, Quintiles Pacific
Michele Yelmene, Executive Director, Clinical and Regulatory Affairs, Perlan Therapeutics

Intellectual Property

SPONSORED BY MORRISON & FORESTER LLP
ROOM 9

1:30pm - 3:00pm

IP Survivor - Realities of Managing your IP Portfolio in the Current Economic and Legal Environments

This workshop will address IP management strategies for increasing the value of an IP portfolio. A distinguished group of panelists will discuss how you can manage costs and yet generate a strategically valuable IP portfolio; how to manage information within your organization to maintain the value of your company's IP; how to manage freedom to operate reviews and what to watch out for when analyzing the effect of competitor's IP; and how to effectively incorporate IP management into your organization's infrastructure, including regulatory and HR concerns. As a reality check, a member from the venture capital industry will comment on IP portfolio strengths to focus upon and common weaknesses to mitigate.

3:30pm - 5:00pm

Full Court Press - Enhancing and Leveraging Your IP Portfolio for Maximum Value

This workshop will address issues concerning IP enforcement and licensing for enhancing the value of an IP portfolio. A distinguished group of panelists will discuss offensive and defensive patent enforcement strategies and considerations for structuring technology alliances and license agreements. Panelists will also address key agreement provisions, valuation, and practical strategies for in-licensing and out-licensing technology.

Human Resources

ROOM IIB

1:30pm - 3:00pm, 3:30pm - 5:00pm

The Nuts and Bolts of Human Resources

Listen and learn innovative and creative ideas for protecting your company's greatest asset, your people. You will have the opportunity to hear HR practitioners share their experiences and offer tangible counsel on how to hire the best and the brightest, how to encourage peak performance, what companies are doing to reward top performers and how to ensure that your company is in compliance with state and federal statutes. You will also learn about other HR practices you can deploy to ensure that your company is on the forefront of change. Our panel of speakers will discuss:

- Hiring the Best - Tools for effective recruitment and selection
- Orientation and Assimilation – What happens after they say "I do"
- Performance Management Systems – Encouraging peak performance
- Postings, Policies and Good HR Practices
- Current Trends in Merit Compensation
- Cultural Transformation – Making the shift from individuals to teams
- Branding and Marketing Your Company
- Coaching and Leadership – How to equip your company for success

Moderator: Diana De Walt, President, The HR Company
Panelists: Linda E. Amuso, Principal, iQuantic - Buck, Inc.
Dennis T. Ferguson, Director, Human Resources, Stratagene
Laurel Marshall, Consultant, Formerly Global Director, Organizational Effectiveness for Johnson & Johnson
Fred Plevin, Managing Partner, Paul, Plevin, Sullivan & Connaughton L.L.P.
Teddi Reilly, Vice President, Human Resources, La Jolla Pharmaceutical Company
Shelley Simmerman-Addy, Director, Human Resources, MitoKor
Mary Yaroshevsky-Glanville, Senior Director, Human Capital, Anadys Pharmaceuticals, Inc.

Purchasing – Basic Contracting

SPONSORED BY VWR INTERNATIONAL
ROOM IIA

The Purchasing and Contracting workshops are designed to help you understand and write the provisions found in every contract, such as warranties, performance, termination, acceptance and indemnification. You will receive and discuss sample clauses written from both a Buyer's and Seller's perspective. In addition, the instructor will provide several form contracts written from the purchaser's perspective. These workshops are hands-on workshops and take a practical approach to understanding and writing contracts.

1:30pm - 3:00pm

Part 1: Understanding the Contract Ts and Cs

- Explanation of key contract concepts an clauses such as consequential and incidental damages, indemnity, and limitation of liability.
- Understanding both the Buyer's and Seller's perspectives concerning these clauses.
- Why these clauses end up in the legal department and how you can assist in their resolution.

2:30pm - 5:00pm

Part 2: Writing the Contract Ts and Cs

- Approaching the reviewing/negotiating/writing of a contract: Taking a macro perspective by identifying and dealing with the major contract issues.
- Applying the macro perspective approach: Class exercise in analyzing 2 typical contracts with which the group is frequently involved
- Break out groups to discuss and write a contract clause.

Speaker: Leslie Marell, Attorney, Law Office of Leslie S. Marell

1:30pm - 3:00pm, 3:30pm - 5:00pm

ROOM 5B

IT Architectures for Tough Economic Times
Are the complexity and cost of running your IT department wearing you down? Would you like to get more from your IT infrastructure without necessarily having to put more into it? Join us for this highly informative workshop. You'll learn about the top 10 things any Chief Information Officer should know and do in tough times and how they are a key component to an efficient and productive IT architecture.

Moderator: Eric Johnson, Senior Systems Engineer, Sun Microsystems
Panelists: Jim Constantine, Senior IT Architect, Sun Microsystems
Richard Rajecki, IT Architect, Sun Microsystems

Tuesday, March 11, 2003 Sessions

8:00am - 10:30am

Breakfast Plenary Session: The Future of Biotech and Pharmaceutical Alliances

SPONSORED BY HELLER EHRMAN

BALLROOM 6CDEF

Executives from Biotech and Big Pharma companies will provide their insights into the future of alliances. Will we continue to see Big Pharma license products and technologies from Biotech? Will there be more consolidation and/or peer-to-peer collaborations between the biotech companies? What impact is the capital market's nuclear winter having on innovation?

Moderator: Fred Frank, Vice Chairman and Director, Lehman Brothers Inc.
Panelists: Joseph C. Cook, Jr., Chairman and CEO, Amylin Pharmaceuticals, Inc.
Stanley T. Crooke, M.D., Ph.D., Founder, Chairman, and CEO, Isis Pharmaceuticals
Richard D. DiMarchi, Ph.D., Group Vice President of Biotechnology and Product Development, Eli Lilly and Company
Alan Proctor, Ph.D., Vice President of Strategic Alliances, Pfizer Inc.
William H. Rastetter, Ph.D., Chairman and CEO, IDEC Pharmaceuticals Corporation
Raymond M. Withy, Ph.D., President, CEO and Director, Abgenix

11:00am - 12:30pm

Track One - SPONSORED BY LATHAM & WATKINS LLP

ROOM 9

Strategies for Survival: Getting Through Hard Times
The failure of a lead compound in Phase III trials or at the FDA is usually the death knell for a company. Some manage to survive and rebuild, and some are acquired by other companies. This panel highlights how these seasoned executives dealt with such critical issues as raising money under extremely adverse conditions; downsizing or rightsizing; the decision to salvage or scrap a lead compound, to salvage or sell the company; explaining the loss of a partner; and dealing with the dark days when the company is in big trouble.

Moderator: Karen Bernstein, Ph.D., Chairman and Editor-in-Chief, BioCentury Publications Inc.

Panelists: Richard B. Brewer, President and CEO, Scios Inc.
Joseph C. Cook, Jr., Chairman and CEO, Amylin Pharmaceuticals, Inc.
Steven J. Mento, Ph.D., President and CEO, Idun Pharmaceuticals
Randall E. Woods, President and CEO, Corvas International

Track Two - SPONSORED BY MENTUS

ROOM IIA

Reimbursement Complexity: Are You Ready?
Current reimbursement complexity demands that payment strategies be included in product launch planning. Are you ready?

Moderator: David L. Gollaher, Ph.D., President and CEO, California Healthcare Institute
Panelists: Ann Gosier, Vice President, Government Affairs, Guidant Corporation
Frank J. Papatheofanis, M.D., MPH, Ph.D., CEO and President, Aequitas Consulting Group
R. Michael Scarano, Jr., Partner, Foley & Lardner
Ruth Suter, Vice President and Senior Analyst, Acumen Sciences

Track Three - SPONSORED BY AVANIR PHARMACEUTICALS

ROOM 10

The Promise (and Disappointments) of Great Science
Great scientific advances over the last decade in genomics, proteomics and high throughput screening have not always led to successful businesses. Great scientific discoveries will only have a commercial impact if they address a market need, such as streamlining a bottleneck in drug discovery. A panel of scientists and analysts will discuss when great science enables great business and when it does not.

Moderator: C. Thomas Caskey, M.D., President and CEO, Cogene Biotech Ventures, Ltd.
Panelists: Thomas J. Dietz, Ph.D., Senior Managing Director, Pacific Growth Equities
Walter H. Moos, Ph.D., Chairman and CEO, MitoKor
Lawrence Souza, Ph.D., Managing Director, Coastview Capital, LLC

Track Four - SPONSORED BY GRAY CARY WARE & FREIDENRICH LLP

The Regulatory Hurdle: Bringing it Across the Line - the FDA Marathon Why do companies hit the wall with their Phase III Clinical Trials?

Moderator: Gerald J. Yakatan, Ph.D., President and CEO, Avanir Pharmaceuticals
Speakers: Gary Firestein, M.D., Professor of Medicine, UCSD School of Medicine
Carl C. Peck, M.D., Georgetown University Medical Center and former Director of Center for Drug Evaluation and Research (CDER)
David Shapiro, M.D., Executive Vice President and Chief Medical Officer, Idun Pharmaceuticals

Track Five

SPONSORED BY ACCENTURE

ROOM 8

The Life Sciences ~ Global IT De facto Standards
The Life Sciences Global IT leaders will present and serve as an interactive panel to address the responsibility that leadership in this highly complex and regulated industry presents. They will discuss their focus on assisting this industry with the challenges of validation, and regula-

tory compliance related to HIPAA and CFR 21 Part 11 and other requirements such security and long term retention of electronic information and data. They will also discuss how their forward vision can assist with converging best practices IT solutions within the multifaceted aspects of discovery and development of medical products.

Moderator: Dorman Followwill, Vice President of Life and Health Sciences, Frost & Sullivan
Panelists: Howard Asher, Global Life Sciences Director, Sun Microsystems, Inc.
Andrew J. Grygiel, Life Sciences Director, Documentum, Inc.
Edward Helton, Ph.D., Principle Strategist, Regulatory Affairs, SAS Institute, Inc. (Invited)
Scott Kahn, Ph.D., Chief Scientific Officer and Senior Vice President, Research and Development, Accelrys
Phil McHale, Vice President, Corporate Communications & Scientific Affairs, MDL Information System, Inc.
Vijay Pillai, Director Life Sciences, Oracle Corporation
Mary Jo Veverka, Life Sciences Partner, Accenture

12:30 – 2:00 pm

Lunch Plenary Session

Shonda Schilling,

Founder of the SHADE Foundation, Wife of Arizona Diamondbacks Pitcher Curt Schilling

Reality Strikes

A real life survivor of malignant melanoma, Shonda Schilling shares her experience battling the most deadly form of skin cancer. For Shonda, accepting the reality that she could die from her condition was the most difficult hurdle to overcome. The wife of a successful Major League Baseball Player and mother of four small children, Shonda found the strength to utilize her high profile situation. She launched a publicity campaign and The Shade Foundation to educate others on melanoma awareness and prevention. Shonda is no stranger to deadly diseases, she is also a supporter and board member of The ALS Association. Cancer free today, Shonda's experience with melanoma and association with ALS will inspire biotech developers by describing the reality of having a potentially deadly disease and living with the hope that the medical industry will enable your survival.

Carl B. Feldbaum,

President, Biotechnology Industry Organization (BIO)

State of the Industry: 2003

Although the biotechnology industry experienced tough times in 2002, the pipeline is packed with late-stage products, including approximately 30 at the NDA and BLA stage. As we celebrate the 50th anniversary of the double helix and the 30th anniversary of recombinant DNA, the industry those discoveries spawned is stronger than ever. In the United States, the industry benefits from a nurturing legal and regulatory environment overall, strengthened by new leadership and fresh energy at the FDA. But biotechnology is increasingly a global phenomenon, as leaders from Texas to Taiwan seek to incubate biotech clusters. In his keynote speech, BIO President Carl B. Feldbaum will provide a snapshot of the state of the biotechnology industry from the local to the global perspective.

2:00pm - 3:30pm

Track One

ROOM 9

Are You Feeling the Urge to Merge: M&A Strategies in Good and Bad Markets

Pressures on companies to grow and retain marketshare, to increase research and development and to consolidate in order to preserve the future financing of the industry are continuing to intensify. Deals, large and small, are coming to fruition throughout the life sciences industry. Debates, however, continue to ensue regarding the perceived merits of strategies associated with mergers and acquisitions and although gains have been realized in many instances, it is certainly not without risks. In this session, financial and biotechnology executives will discuss recent trends in the industry and evaluate the potential and possible reasons for mergers and acquisitions.

Moderator: David Mack, Ph.D., Director, Alta Partners
Panelists: Michael Brinkman, Managing Director, Life Sciences, CIBC World Markets
Alan C. Mendelson, Partner, Latham & Watkins
Jack W. Reich, Ph.D., Founder and Former CEO, Collateral Therapeutics
John P. Walker, Chairman and CEO, Bayhill Therapeutics, Inc.

Track Two

ROOM IIA

The Art and Science of Launching a Product: From Countdown to Liftoff Strategic Management of Your Product Launch is a Make-or-Break Proposition

In today's business environment, life science companies working on early-stage products are experiencing a nuclear winter, – investors want companies with products that are closer to FDA approval and market launch. All seek the next blockbuster. Therefore, exceptional marketing campaigns with well-planned strategies are essential to optimizing market uptake. Companies often make critical missteps when it comes to marketing. First, they fail to begin the process early enough (i.e., at least two years from product approval). Second, excited scientists persuade company executives that the product will "jump off the shelves" and sell itself. Third, critical market research is either stale or undertaken too late. And finally, companies underestimate the time and budget needed to successfully propel and sustain a world-class product launch.

Navigating this tricky maze is as critical and difficult as developing a revolutionary drug and requires legal, regulatory, and marketing finesse.

A distinguished panel of industry leaders with decades of experience launching pharmaceutical and biotech products will share their insights, including an overview of the pharmaceutical launch process, with an examination of the best strategies to brand and differentiate products effectively.The panelists will share compelling case examples and will examine advertising and promotion, pricing strategies, partnering and direct to consumer tactics and other hot current issues.

Moderator: Guy J. Iannuzzi, President, Mentus
Chuck Howe, Vice President of Sales, IDEC Pharmaceuticals Corporation
Martin Mattingly, Vice President and General Manager, Pfizer/Agouron Pharmaceuticals
Diane Romza-Kutz, Partner, Mayer, Brown, Rowe & Maw
Mark R. Van Ausdal, Counsel, Mayer, Brown, Rowe & Maw

Track Three

ROOM 10

Changing Models: What Do You Want to Be When You Grow Up?

Spelling success in many configurations, senior executives will discuss transitioning from genomics to product development. The panel will also explore how value can be created from out-licensing programs from pharmas and large biotechs. Questions to be addressed include what goals should drive emerging biotech companies and striking the appropriate balance between platform/discovery and product development/acquisitions.

Moderator: Mike Grey, Chief Business Officer, Structural GenomiX, Inc.

Panelists: Keith E. Dionne, Ph.D., Vice President and General Manager, Millennium Pharmaceuticals

Geoffrey Duyk, M.D., Ph.D., Executive Vice President and Chief Scientific Officer, Exelixis

John A. Scarlett, M.D., President & CEO, Tercica Medica, Inc.

W. Scott Harkonen, M.D., President and CEO, InterMune, Inc.

Track Four

ROOM IIB

"60 Minutes is Calling...?" – Facing Ethical Issues In Clinical Trials

When Ed Bradley calls is not the time to start facing ethical issues. This panel of experts - starting with a case study, led by one of the senior executives involved, of a real ethical crisis Elan faced on a trial involving a potentially blockbuster drug – will explore not only the underlying principles governing ethical conduct of clinical studies, but also how to be prepared in advance to anticipate, identify and deal with ethical challenges; resolving properly the tension between business and ethical/moral concerns; and, in the worst case, tips on how to effectively address a crisis as it unfolds in real time.

Moderator: Michael A. Swit, Esq., Special Counsel, Heller Ehrman

Panelists: Lars Ekman, M.D., Ph.D., President, Research and Development, Biopharmaceuticals, Elan Corporation

Linda G. Strause, Ph.D., Global Clinical Project Advisor, CancerVax Corporation

Felix A. Khin-Maung-Gyi, Pharm.D., Founder and CEO, Chesapeake Research Review, Inc.

Track Five

ROOM 8

The Global Life Sciences – IT Consortium: Creating Integrated Structures To Speed The Development Process

The explosion of data and information cascading from initiatives such as the Human Genome Project has created a dilemma. Increasingly complex processes can no longer be performed, reviewed or validated based solely on paper-based records. The paradigm shift towards digital data is being driven by advances such as computational biology and combinatorial chemistry and in silico experiments will require data transfer rates and data integrity that can't be attained in the current system.

It is widely accepted that digital data and information technology solutions will result in more efficient drug discovery/development. However, obtaining timely regulatory approval to bring critically needed new drugs to market will remain a major hurdle. Advances in information technology must be understandable and trustworthy to regulatory bodies. Thus, the universal adoption of test beds and standards to ensure the authenticity, integrity, trustworthiness and privacy of electronic records is critical in order to significantly shorten the time to market and reduce the cost involved in the drug discovery/development/market approval process. This panel, made up of members of the newly formed Life Sciences-IT Consortium, will address how the life science, information technology and regulatory communities can work together to reduce the time and cost associated with the discovery and development of therapeutics and other medical products.

Moderator: M. Wainwright Fishburn, Jr., Partner, Cooley Godward

Panelists: Howard Asher, Group Director, Global Life Sciences Group, Sun Microsystems

Philip E. Bourne, Ph.D., Professor of Pharmacology, Director, Integrative Biosciences, San Diego Supercomputer Center

Adam Godzik, Ph.D., Associate Professor and Program Director Bioinformatics and Biological Complexity Program, The Burnham Institute

Edward W. Holmes, M.D., Vice Chancellor, Dean, Health Sciences, UCSD School of Medicine

Greg Horowitt, Director, Corporate Connections, UCSD CONNECT

4:00pm - 5:30pm

Track One

ROOM 9

Let's Make a Deal

In this highly interactive session, the audience will have the opportunity to witness what can sometimes be a terrifying and painful experience. Several courageous companies have volunteered to give their financing pitch to an all-star panel of vulture capitalists (a.k.a. venture capitalists). The audience and the panel of veterans will have a chance to analyze and interrogate the strengths and weaknesses of the management team, the business strategy, investment rationale and other elements of the company's presentation. After each short presentation, the audience will have a chance to compare their assessments with those of the panel, promising a first hand look at the VC's decision making process and why a company receives the funding it needs or gets eaten for lunch.

Moderator: Nandini Tandon, Ph.D., Partner, RBC Capital Partners

Panelists: Luke Evnin, Ph.D., General Partner, MPM Capital

Arthur J. Klausner, General Partner, Domain Associates

Robert W. Overell, Ph.D., General Partner, Frazier Healthcare Ventures

Drew Senyei, M.D., Managing Director and General Partner, Enterprise Partners Venture Capital

Kenneth J. Widder, M.D., General Partner, Windamere Venture Partners

Track Two

ROOM IIA

State of the Medical Device Industry

If you can make it, can you sell it? Does the old paradigm still hold? A panel of leading medical device experts will discuss the most pressing issues facing their industry today.

Moderator: J. Casey McGlynn, Partner, Wilson Sonsini Goodrich & Rosati

Panelists: Peter C. Farrell, Ph.D., Executive Chairman, ResMed

Michael Ziering, President and CEO, Diagnostic Products Corporation

Schedule

Track Three

ROOM 10

Intellectual Property: The Picket Fence Strategy

Great discoveries are only good if you can commercialize them. Successful commercialization can take place only with effective IP protection. Panelists will explain how they have staked their claims to protect important product rights.

Moderator: Ted Greene, Jr., Co-Founder, Amylin Pharmaceuticals, Inc.
Panelists: Vern Norviel, Wilson Sonsini Goodrich & Rosati
B. Lynne Parshall, J.D., Executive Vice President and CFO, Isis Pharmaceuticals, Inc.
William L. Respess, Vice President and General Counsel, Applied Molecular Evolution, Inc.

Track Four

ROOM 11B

Corporate Governance: Best Practices for Success

Dispelling the atmosphere of cynicism and distrust among investors, consumers, physicians, and patients will require a careful blend of compliance with SEC regulations and accounting principles. However, the ever-changing landscape requires that corporations manage not only their balance sheets and boards, but also their internal and external reputations. Rebuilding trust now requires strict compliance – built upon a generally recognized and accepted moral and ethical foundation. This panel of regulatory experts and business ethicists will explore how to overcome the crisis in confidence to build a culture of corporate and personal accountability within an organization.

Moderator: Shirli Fabbri Weiss, Partner, Gray Cary Ware & Freidenrich
Panelists: Dana F. Kopper, CIC, ARM, Senior Vice President, Marsh, Inc.
John Marchica, Founder and CEO, FaxWatch Inc.
Chris W. Nolet, Partner, Ernst & Young

Track Five

ROOM 11B

BioUtility: A Cross-Company Computer Network That Benefits All. Yes: It Can and Is Being Done

Do you have a need to share information and data with other biotech companies and life science companies? Do you have concerns over the security and confidentiality of sharing this information over the public internet? Would you like to generate new revenue streams by sharing data or services across such a network? Would you like to expand computing resources without the acquisition of more expensive hardware and software? Through a real case study, this session will provide you with the necessary insight to see the strategic business value of leveraging BioUtility networks.

Panelists: Jeffrey Augen, President, Turboworx
Chuck Lane, Systems Architect, Biomedical Informatics Research Network (BIRN)
Eric Lawrence, Director of Sales, Life Science & Healthcare, Sun Microsystems Canada
Dr. Wolfgang Gentzsch, Director of Grid Computing, Sun Microsystems

Sponsors

Platinum Sponsor

Sun microsystems
We make the net work.

Plenary Sponsor

HellerEhrman ATTORNEYS
Challenging the laws of convention.™

Gold Sponsors

Cooley Godward LLP

FOLEY LARDNER ATTORNEYS AT LAW

LifeSci TECHNOLOGIES

Annual Dinner Sponsor

Pfizer La Jolla

Session Sponsors

accenture
Innovation delivered.

AVANIR pharmaceuticals

GRAYCARY.
TECHNOLOGY'S LEGAL EDGE®

LATHAM&WATKINS LLP

mentus

Workshop Sponsors

susan e. ATKINS ASSOCIATES
bio-business communications

Deloitte & Touche

ERNST & YOUNG

MoFo
MORRISON & FOERSTER LLP
Lawyers for the global economy™

VWR INTERNATIONAL

Partner Sponsors

Arena

CancerVax Corporation

Celgene

IDEC Pharmaceuticals Corporation

invest-UK

Co-Host Sponsors

C·H·I California Healthcare Institute
The Advocate for California's Biomedical Industry

UCSD CONNECT
where entrepreneurs come for results™

Media Sponsors

the Sector EVERYTHING TECH SAN DIEGO

Business Wire
The Global Leader in News Distribution

Lanyard Sponsor

MARSH

Meeting Bag Sponsor

Woodruff-Sawyer & Co.
an Assurex Global Partner

Refreshment Break Sponsors

Harlan

Knobbe Martens Olson & Bear LLP
Intellectual Property Law

Endorsing Sponsors

Bio BIOTECHNOLOGY INDUSTRY ORGANIZATION

ComericA

C | M | T | C

DPR Construction Inc.

LIGAND® PHARMACEUTICALS

MAXIM PHARMACEUTICALS

Silicon Valley Bank

Supporting Sponsors

Amylin Pharmaceuticals, Inc.
Aztec Business Machines
Beckman Properties
BioSpace
Bristol Myers Squibb
Canji
Chubb Group of Insurance Companies
Elan Pharmaceuticals
Four Square
La Jolla Pharmaceutical Company
San Diego Gas & Electric
SignOnSanDiego.com
The Pidgeon Company Corporate Housing

Affiliate Sponsors

BioSite Inc.
Corvas International
Diversa Corporation
Genomic Institute of the Novartis Research Foundation
Idun Pharmaceuticals
Pricewaterhouse Coopers LLP



Heller Ehrman v. The System

After forty years of helping revolutionize the Life Sciences, Heller Ehrman is renowned for navigating complex legal, financial and regulatory roadblocks. But challenging systems means more than grasping the central nervous system of law. It means keeping our finger on the pulse of science and having infinite respect for the challenges of improving and prolonging human life.

HellerEhrman
ATTORNEYS

Challenging the laws of convention.™

CALBIO Speakers

Plenary Speakers

CARL B. FELDBAUM, President, Biotechnology Industry Organization (BIO)

Carl B. Feldbaum is president of the Biotechnology Industry Organization (BIO) in Washington, D.C., which represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health care, agricultural, industrial and environmental biotechnology products.

Mr. Feldbaum came to Washington D.C. in 1973 as an assistant special prosecutor for the Watergate special prosecution force to work with Archibald Cox to investigate and prosecute the Watergate scandal.

Prior to his appointment as president of BIO, Mr. Feldbaum was chief of staff to Senator Arlen Specter (R-PA) of Pennsylvania. He was also president and founder of the Palomar Corporation, a national security "think tank" in Washington, D.C. Before founding Palomar Corporation, Mr. Feldbaum was assistant to the Secretary of Energy, and served as the Inspector General for defense intelligence in the U.S. Department of Defense.

In 1979, Mr. Feldbaum was awarded the Distinguished Civilian Service Medal from Defense Secretary Harold Brown. He received the Christopher Medal for his book "Looking the Tiger in the Eye: Confronting the Nuclear Threat," which was also designated by the New York Times as a notable book of the year for 1988.

Mr. Feldbaum received a bachelor's degree in biology from Princeton University and his law degree from the University of Pennsylvania Law School.

SHONDA SCHILLING, Founder of the SHADE Foundation, Wife of Arizona Diamondbacks Pitcher Curt Schilling

Shonda Schilling, wife of Arizona Diamondbacks pitcher Curt Schilling, is a woman raising awareness and funding for people affected by amyotrophic lateral sclerosis (ALS), as well as being a loving mother of four children and a melanoma survivor.

ALS, or Lou Gehrig's disease, is a neuromuscular disease which makes it increasingly difficult for those affected to walk and speak, and it eventually leads to paralysis and death. Shonda became a mouthpiece for the cause in 1992 when she joined the Philadelphia chapter of the ALS Association. Now, 10 years later, Shonda sits on the board for both Philadelphia and Arizona chapters. She represents ALS at numerous functions including testifying before Congress in Washington D.C. for government funding.

While Shonda spends a great deal of time working with ALS victims, she has also been fighting a battle of her own after being diagnosed with skin cancer in 2001. Thankfully, her melanoma was discovered early and after five surgeries all of the cancer has been removed. Shonda is now a national spokesperson for the American Academy of Dermatology along with various other melanoma foundations. She has appeared on Good Morning America, The View, CNN Today, and numerous local Phoenix and Philadelphia TV stations. Shonda's story has been featured in Glamour, Parade, People, Pregnancy, Raising Arizona Kids Magazine and many other national and local publications to promote the need to practice responsible sun habits.

A native of Maryland, Shonda graduated from Towsen State College with a degree in journalism. She worked as an associate producer for Home Team Sports in Baltimore, M.D. Shonda was a semi-finalist in the Ms. Maryland pageant.

Diverse Perspectives...
An Integrated Approach

Foley & Lardner's Life Sciences Industry Team integrates the extensive resources of a national law firm in health care, intellectual property, business and regulatory law to serve the diverse needs of enterprises at the cutting edge of applied biology. We provide clients a unified perspective on building and defending intellectual-asset value, on establishing and managing strategic collaborations worldwide, and on finding the most direct path to the marketplace.

Our team is enriched by backgrounds that include advanced degrees and working experience in key technical disciplines, such as molecular biology, immunology, proteomics, and pharmaceutical chemistry. In North America, Europe, and the Far Pacific Rim, we serve the biotech, pharma, and biomedical sectors by combining technological and legal insights with a commitment to client service. To learn more, please call Ken Klein at 619.685.6449 or visit us on the Web at www.**foleylardner**.com.

FOLEY LARDNER

ATTORNEYS AT LAW

BRUSSELS
CHICAGO
DENVER
DETROIT
JACKSONVILLE
LOS ANGELES
MADISON
MILWAUKEE
ORLANDO
SACRAMENTO
SAN DIEGO
SAN DIEGO/DEL MAR
SAN FRANCISCO
TALLAHASSEE
TAMPA
WASHINGTON DC
WEST PALM BEACH

Breakfast Plenary Panelists

JOSEPH C. COOK, JR., Chairman and CEO, Amylin Pharmaceuticals, Inc.

Mr. Cook has been Chairman and CEO of Amylin Pharmaceuticals, Inc. since March 1998 and a Board member since 1994. He also sits on the Boards of Microbia, Inc., American Diabetes Association Research Foundation and Corcept Therapeutics, Inc. and acts as an advisor to the Board of Boehringer Ingelheim Corp. U.S.

STANLEY T. CROOKE, M.D. Ph.D., Founder, Chairman and CEO, Isis Pharmaceuticals

Stanley T. Crooke, M.D., Ph. D., is founder, chairman and CEO of Isis Pharmaceuticals. Isis Pharmaceuticals is exploiting its expertise in RNA to discover and develop novel human therapeutic drugs. Founded in 1989, Isis has made significant progress in advancing antisense technology and its rapid conversion to therapeutic product opportunities. Dr. Crooke currently serves as a member on the Board of Directors for several biotechnology companies. He is an active advisory member for the number of key scientific journals and serves as editor-in-chief of Current Opinion in Anticancer Drugs and section editor for Biologicals and Immunologicals for Expert Opinion on Investigational Drugs. During his career, Dr. Crooke has supervised the development of 19 drugs currently on the market and others in development.

RICHARD D. DIMARCHI, Ph.D., Group Vice President, Eli Lilly Research Laboratories

Richard DiMarchi is Group Vice President at Eli Lilly and Company and a member of Eli Lilly senior management. He maintains responsibilities for investments in cutting-edge research technologies, and Product Development. He joined Eli Lilly and Company in 1981, after advanced academic training at Indiana University and the Rockefeller University. He previously served as Vice President of Endocrine Research and Executive Director of Biochemistry. He currently serves as Chairman of the Indiana Proteomics Consortium, a commercial enterprise co-owned by Indiana University, Purdue University and Eli Lilly & Company. He is a Board member of ARTI (Advanced Research and Technology at Indiana University) and a member of the University Science Advisory Committee.

FRED FRANK, Vice Chairman and Director, Lehman Brothers Inc.

Before joining Lehman Brothers as a Partner in October, 1969, Mr. Frank was co-director of research, as well as Vice President and Director, of Smith, Barney & Co. Incorporated. He is a Chartered Financial Analyst, a member of The New York Society of Security Analysts and a past president of the Chemical Processing Industry Analysts. In 1998, Mr. Frank was honored for Outstanding Contributions in the Field of Immunology by the Irvington Institute for Immunological Research, and, in 1997, he received the Biotech Meeting at Laguna Niguel Hall of Fame Award for Special Recognition for an Individual. Mr. Frank has provided investment banking services to a host of companies in the pharmaceutical, biotechnology, medical device and nutraceutical industries, and has been involved in hundreds of financings and merger and acquisition transactions in the health care field.

ALAN PROCTOR, Ph.D. Vice President, Strategic Alliances, Pfizer Global Research and Development

Alan Proctor is responsible for managing the establishment and growth of the Strategic Alliances globally. In his 30 years at Pfizer, Dr. Proctor pioneered the applications of gene splicing and high through put screening technologies to the discovery process, led teams in cancer, immunology, infectious disease discovery and was founder of the Pfizer Discovery Technology Center in Cambridge, MA.

WILLIAM H. RASTETTER, Ph.D., Chairman and CEO, IDEC Pharmaceuticals Corporation

Dr. Rastetter was appointed chairman of the Board of Directors of the company on May 22, 1996. He served as President and CEO of the company from December 1986 until January 2002. He turned over the title of President to Bill Rohn in January 2002. Dr. Rastetter was also CFO from 1988 to 1993. Dr. Rastetter has served as Director of the company since 1986. From 1984 to 1986, he was Director of Corporate Ventures at Genentech, directing the Biocatalysis and Chemical Sciences groups. From 1975 to 1982 he held various positions at the Massachusetts Institute of Technology. Dr. Rastetter received his Ph.D. in chemistry from Harvard University in 1975. In addition he serves on Governor Gray Davis' Bio-Science Council and as a director of the California Healthcare Institute (CHI).

RAYMOND WITHY, Ph.D., President and Chief Executive Officer, Abgennix

Raymond Withy has served as President and Chief Executive Officer of Abgenix since May 2002 and as President and Chief Operating Officer since January 2001. Dr. Withy joined Abgenix at its inception in July 1996 as Vice President of Corporate Development, and in January 2000, became Chief Business Officer of the company. Prior to Abgenix operating independently as a subsidiary of Cell Genesys, Dr. Withy spent three years at Cell Genesys, as Director of Business Development. Prior to Abgenix and Cell Genesys, Dr. Withy held various research and development positions at Genzyme Corporation and Integrated Genetics, Inc. Dr. Withy received his Ph.D. in Biochemistry from the University of Nottingham in the U.K. and was a post-doctoral fellow at the California Institute of Technology.



Counselors, strategists,
and advocates—
serving the specialized
legal needs of the biotech
industry since 1975.

BIOTECH LEGAL SPECIALISTS

Cooley Godward has earned its reputation as the preeminent counsel for life sciences companies. We provide the most comprehensive legal services and support to the biotech industry:

- Access to Capital
- Corporate Finance
- Mergers and Acquisitions
- Corporate Partnering & Product Commercialization
- Patent Strategy & Litigation

For more information,
call 858/550-6000.

The law firm of choice for over 200 biotech companies nationwide, including 50% of the companies on the Nasdaq Biotechnology Index.

Cooley Godward LLP

www.cooley.com

Breakout Session Panelists

HOWARD ASHER, Group Director of Global Life Sciences, Sun Microsystems, Inc.

Howard began his career in life sciences in 1969 with Pfizer. He continued his marketing, sales and product development work with Baxter and Bayer until 1979. Late in 1979, he founded Advanced Bioresearch Associates (ABA), which grew to be the premier Life Sciences - FDA Regulatory Affairs consulting firm for Life Science company clients, worldwide. ABA strategically focused to make business sense of developing medical products in a heavily regulated environment. Howard served as President, CEO and Chairman of ABA for 20 years, securing regulatory approval for hundreds of medical products, including drugs, biotherapeutics, medical devices and in-vitro diagnostics.

KAREN BERNSTEIN, Ph.D., Chairman and Editor-in-Chief, BioCentury Publications Inc.

Karen Bernstein is Co-Founder, Chairman and Editor-in-Chief of BioCentury Publications Inc., which provides business-oriented information services for biotechnology managers and investors. The company publishes BioCentury, the Bernstein Report on BioBusiness, which specializes in analysis, interpretation and commentary on issues affecting the biotechnology industry. Additional titles include BioCentury Extra, a Web-based daily news service and BioCentury Part II, a weekly compendium of corporate, clinical and financial news. Dr. Bernstein, who has been writing and publishing on biotechnology topics since 1987, holds a Ph.D. in political science from Stanford University.

PHILIP E. BOURNE, Professor of Pharmacology, Director of Integrated Biosciences, San Diego Supercomputer Center

Professor Philip Bourne received his Ph.D. in chemistry from the Flinders University of South Australia in 1980 where he studied the structural and electrophilic effects of substitution on fully saturated caged hydrocarbon molecules. While a post-doctoral fellow at Sheffield University UK he contributed to the understanding of the structural role of the protein ferritin in iron storage. Later as a Senior Research Scientist at Columbia University in New York he proposed mechanisms for the role of caracurines and snake toxins that operate postsynaptically. During the 80's as first the Director of the Cancer Center Computer Facility and later Director of the Medical School Computer Facility at Columbia University he established a tumor registry and various applications and databases in support of patient care. In the early 90's as a Senior Associate of the Howard Hughes Medical Institute he worked on developing high performance hardware and software for computational structural biology.

RICHARD S. BREWER, President and CEO, Scios Inc.

Mr. Brewer brings to his leadership role at Scios extensive experience in the biopharmaceutical industry, particularly in marketing, drug development and clinical trials. Mr. Brewer joined Scios in September 1998 and has also served as a member of the Scios Board of Directors since that time. From 1996 to 1998, he was with Heartport Inc., a cardiovascular device startup, first as Executive Vice President of Operations and then Chief Operating Officer. Prior to that, Mr. Brewer served in various capacities with Genentech, Inc. from 1984 to 1995, most recently as Senior Vice President, U.S. Sales and Marketing, Genentech Europe Ltd., and Genentech Canada, Inc.

MICHAEL BRINKMAN, Managing Director, CIBC World Markets

Michael Brinkman is a Managing Director in the Healthcare Investment Banking Group at CIBC World Markets. He has been with CIBC since April 1994, during which time he has become one of the most active investment bankers in the biotechnology arena. He leads CIBC's biotechnology effort on the West Coast, and has extensive experience in public and private financings, and in advising companies on mergers and acquisitions. Prior to joining CIBC World Markets he was Director, Product Development at The Holden Group, a Los Angeles life insurance company. Previously, he headed product development for a leading South African health insurer, Crusader Life. Mr. Brinkman received his B.S. (Magna Cum Laude) from the University of the Witwatersrand in South Africa, and his Fellows.

C. THOMAS CASKEY, M.D., F.A.C.P., Cogene Biotech Ventures, Ltd.

Dr. Caskey is CEO and President of Cogene Biotech Ventures, Ltd. He served as Senior Vice President for Human Genetics and Vaccines Discovery at Merck Research Laboratories, West Point, PA and as President of the Merck Genome Research Institute. He serves as an Adjunct Professor for the Department of Molecular & Human Genetics at Baylor College of Medicine in Houston, Texas. Dr. Caskey earned his medical doctorate from Duke University, Durham, NC. He is a member of the National Academy of Sciences and Institute of Medicine. He is the Past President of American Society of Human Genetics and the Human Genome Organization. He served as Chair, Advisory Panel on Forensic Uses of DNA Tests, U.S. Congress Office of Technology Assessment, 1989-1990. He serves on Texas Governor Perry's 2002 Council on Science and Biotechnology Development and on the President's Advisory Council of Austin College.

THOMAS J. DIETZ, Ph.D., Senior Managing Director, Pacific Growth Equities

Tom joined Pacific Growth in 1993 as the Senior Biotechnology/ Biopharmaceutical Analyst and currently serves as the Senior Managing Director in Research. His is a leading voice on Wall Street for biotechnology stocks. Prior to joining Pacific Growth, Tom was a Research Faculty member at U.C. San Francisco, and his research has been funded by the National Institutes of Health, the National Science Foundation and NASA.

KEITH E. DIONNE, Ph.D., Vice President and General Manager, Millennium Pharmaceuticals

Dr. Dionne is Vice President and General Manager of Technology Business for Millennium Pharmaceuticals Inc. He is responsible for building Millennium's Technology Solutions Business wherein Millennium provides technology solutions to the life sciences sector and for building Millennium's technology platform through external technology acquisition and collaborations. Previous to this role, Dr. Dionne was responsible for program management across Millennium's Technology Development division and for managing Millennium's technology collaborations including the Functional Genomics Consortia at the Whitehead Institute. Dr. Dionne has been an Adjunct Professor in the Biomedical Department at Brown University and received his Ph.D. in Chemical Engineering and his M.S. in the Program for Technology Policy both at the Massachusetts Institute of Technology.

INNOVATIVE PHARMACEUTICAL PRODUCTS FOR SERIOUS DISEASES





Pfizer

La Jolla

Agouron® Pharmaceuticals, Inc.
A Pfizer Company

Pfizer La Jolla

10777 Science Center Drive
San Diego, CA 92121

GEOFFREY DUYK, M.D., Ph.D., Executive Vice President and Chief Scientific Officer, Exelixis

Dr. Duyk joined Exelixis in April 1997 from Millennium Pharmaceuticals, where he was one of the founding scientific staff. As Vice President at Genomics at Millennium, he was responsible for building and leading the informatics, automation, DNA sequencing and genotyping groups as well as the mouse and human genetics group. Prior to his tenure at Millennium, Dr. Duyk was an Assistant Professor of Harvard Medical School (HMS) in the Department of Genetics and Assistant Investigator of the Howard Hughes Medical Institute (HHMI). While at HMS, Dr. Duyk was a Co-Principal Investigator in the National Institutes of Health (NIH) funded Cooperative Human Linkage Center. Dr. Duyk is a member of numerous NIH panels and oversight committees focused on the planning and execution of the human genome project. Dr. Duyk holds a Ph.D. and M.D. from Case Western Research University and following the completion of his medical and fellowship training at University of California, San Francisco, was the only person to have been awarded both a Markey fellowship and a HHMI post-doctoral fellowship.

LARS EKMAN, M.D., Ph.D., President, Research and Development, Biopharmaceuticals, Elan Corporation

Dr. Lars Ekman was appointed President, Research and Development, Elan Pharmaceuticals in January 2001. Prior to joining Elan, he was responsible for research and development at Schwarz Pharma AG since 1997. He is a board certified surgeon with a Ph.D. in experimental biology and has held several clinical and academic positions in both the United States and Europe. From 1984 to 1997, Dr. Ekman was employed in a variety of senior scientific and clinical functions in what today is Pharmacia Corporation. He obtained his Ph.D. and M.D. from the University of Gothenburg, Sweden.

LUKE EVNIN, Ph.D., General Partner, MPM Capital

Dr. Evnin is a General Partner at MPM Capital. Before joining MPM, Dr. Evnin was at Accel Partners for more than seven years including four years as a General Partner. He was involved in biopharmaceutical, pharmaceutical, medical device and healthcare service companies for Accel's funds III, IV and V. He was responsible for healthcare investment strategy, deal origination, analyses, investment and gain realization. Dr. Evnin began his career in the field of science. He earned his Ph.D. in the Department of Biochemistry at the University of California San Francisco, and he received his A.B. in Molecular Biology magna cum laude from Princeton University. Dr. Evnin is currently Director of EPIC Therapeutics, GeneSoft, Metabasis, Pi Medical, and Venturi Group, and was previously a Director at Atugen, CHF Solutions, BioValve, Medical SelfCare, EPIX Medical and several other private companies.

PETER C. FARRELL, Ph.D. DSc FTSE FIE Aust FAIM FAICD, Executive Chairman, ResMed

Peter C. Farrell has been President and a director since ResMed's inception in June 1989 and Chief Executive Officer since July 1990. From July 1984 to June 1989, Dr Farrell served as Vice President, Research and Development at various subsidiaries of Baxter International, Inc. ("Baxter") and from August 1985 to June 1989, he also served as Managing Director of the Baxter Center for Medical Research Pty Ltd, a subsidiary of BaxterHe holds a BE. in chemical engineering with honors from the University of Sydney, an SM. in chemical engineering from the Massachusetts Institute of Technology, a Ph.D. in chemical engineering and bioengineering from the University of Washington, Seattle and a DSc from the University of New South Wales. Dr Farrell was named 1998 San Diego Entrepreneur of the Year for Health Sciences and Australian Entrepreneur of the Year in 2001. In August 2000, he was named Vice Chairman of the Executive Council of the Harvard Medical School Division of Sleep Medicine.

GARY FIRESTEIN, M.D., Professor of Medicine, UCSD School of Medicine

Gary Firestein, M.D., is Professor of Medicine and Chief of the Division of Rheumatology, Allergy and Immunology, University of California, San Diego School of Medicine. His expertise is in rheumatoid and other forms of arthritis and autoimmune diseases, particularly in the areas of synovial biopsies, and the evaluation of synovial gene expression. Dr. Firestein has authored more than 160 papers and chapters and is co-editor of The Kelley Textbook of Rheumatology. He is Chairman of the FDA Arthritis Advisory Committee.

M. WAINWRIGHT FISHBURN, JR., Partner, Cooley Godward

Wain Fishburn is a founding partner of Cooley Godward, San Diego. His practice concentrates on board level counseling, public offerings, venture financings and strategic alliances including life sciences. Wain has assisted as counsel to numerous start-ups, is a founder of a public biotech company and as a Cooley partner served as acting general counsel of the Titan Corporation. He has also represented U.S., European and Japanese companies in international transactions of varying descriptions. He is a founding director of BIOCOM/san diego and the Corporate Directors Forum, and is past president of the Connect Financial Forum and has served on several boards including the San Diego Venture Group. He currently serves on the Burnham Institute Board of Trustees.

DORMAN FOLLOWWILL, Vice President, Healthcare & Life Sciences

Mr. Followwill has over 18 years of experience, both in the business sector and as a manager in non-profit organizations. He began his consulting career as a management consultant with Marakon Associates in San Francisco. While there, his primary engagements were to manage the development of a profitability reporting system for a multi-billion dollar savings institution, to conduct an acquisitions analysis for a commercial construction firm, and to perform various other product and market evaluations. Dorman has worked for Frost & Sullivan for over six years, having overseen the custom market research consulting enterprise in its early stages of development, as well as managing the healthcare business unit. Dorman has managed a wide variety of consulting engagements, including strategic analyses for IBM Life Sciences, 3M, Johnson & Johnson, Bayer (Diagnostics and Biologicals), Chiron, Agilent, Smith & Nephew, Baxter Healthcare, GlaxoSmithKline, Kimberly-Clark, Novo Nordisk, Amersham Biosciences, AmeriNet, Thermo Electron, and many others.

ADAM GODZIK, Ph.D., Professor and Program Director, Program for Bioinformatics and Systems Biology, The Burnham Institute and Bioinformatics Core Leader, Joint Center for Structural Genomics, UCSD

Dr. Godzik is a scientist applying tools of physics and computer science to analyze biological systems by developing protein structure and function prediction algorithms. Dr. Godzik received Ph.D. in physics from University of Warsaw, Poland and before joining the Burnham Institute worked at EMBL in Heidelberg and the Scripps Research Institute in La Jolla. He is a co-founder of Geneformatics Inc. (recently merged with the Structural Bioinformatics Inc.) and founder and CEO of Protein Vision Inc., recently acquired by Quorex Pharmaceuticals.

AVANIR
pharmaceuticals



THE WAY WE THINK ABOUT DRUG DEVELOPMENT



Abreva®

Neurodex

IgE

Our focus is on products

Our defined discovery and smart development processes are the heart and soul of AVANIR. It starts with an open-minded attitude toward drug discovery that doesn't focus on just one technology, one target, or one disease area. Instead it emphasizes effectively triaging drug candidates, eliminating or reducing known discovery hurdles, embracing in-licensed compounds as viable candidates, and identifying worthwhile market opportunities. By being nimble in our decision making, we can remain focused on our overall goal of adding value to each product, for our partners and for all our shareholders.

Your invited to visit our website to learn more **www.avanir.com**

DAVID L. GOLLAHER, Ph.D, President and CEO, California Healthcare Institute

Dr. Gollaher is President and CEO of the California Healthcare Institute (CHI), a statewide public policy organization, representing California's leading academic institutions, biotechnology, medical device, diagnostic and pharmaceutical companies. Before joining CHI in 1993, Dr. Gollaher served on the faculties of the SDSU Graduate School of Public Health, and UCSD. He earned his bachelor's degree at UCSB, and Masters and Ph.D. degrees from Harvard University. Between 1985-1991, Dr. Gollaher was a Vice President at Scripps Clinic and Research Foundation in La Jolla, California. Prior to joining Scripps, he held executive positions with Young & Rubicam New York, and McCann Erikson. In 1998, Governor Davis appointed Dr. Gollaher to California's advisory commission on human cloning.

ANN GOSIER, Vice President, Government Affairs, Guidant Corporation

Ann serves as vice president, government affairs and the head of the Washington, DC office for Guidant Corporation, a leading designer and manufacturer of medical technologies used primarily to treat cardiovascular and vascular illnesses. She joined Guidant in September 1996. Prior to joining Guidant, she served as executive director of the Product Liability Coordinating Committee (PLCC), a broad-based, cross-industry coalition of companies and trade associations advocating enactment of legal reforms. Earlier in her career, Ann served as vice president of a national trade association; was on the staff of a member of Congress; and worked for national public affairs and political consulting firms. Ann is a graduate of Trinity College (DC) with a degree in political science.

TED GREENE

Ted Greene is a retired entrepreneur who has participated in the founding and/or management of nine medical technology companies and one venture capital firm. From 1987 to 1996 he served as CEO of Amylin Pharmaceuticals. Greene was a general partner of Biovest Partners and CEO of Hybritech Incorporated. He has been an executive with Baxter and a consultant with McKinsey. He serves on the boards of Amylin, Biosite, and Epimmune.

MIKE GREY, Chief Business Officer, Structural GenomiX, Inc.

Mike Grey is Chief Business Officer and a director of Structural GenomiX, Inc., a San Diego structure-based drug discovery company. Mike has held senior positions in a number of North American Biotechnology companies, including CEO of Trega Biosciences, Inc. and President of BioChem Therapeutic, Inc. From 1974 to 1993, Mike served in various roles with Glaxo, culminating in his position as VP, Corporate Development. Mike also serves on the board of several U.S. biotechnology companies.

ANDREW J. GRYGIEL, Life Sciences Industry Director, Documentum, Inc.

Andrew Grygiel is responsible for Documentum's Life Sciences thought leadership and business and marketing strategies. Andrew has over 20 years of experience designing, developing, and marketing information technology solutions to the Life Sciences marketplace. Prior to Documentum, Andrew was the Vice President of Marketing at Innaphase Corporation, a leading provider of regulatory compliant technology solutions for Life Sciences research and development. While there, Andrew was responsible for managing the product management, product marketing and corporate marketing functions. Prior to InnaPhase, Andrew held a number of senior management positions at leading life science focused technology companies such as Chemdex, Hewlett Packard (Agilent), and Perkin-Elmer (Applied Biosystems). Andrew began his career as a chemist at National Medical Services, an independent bioanalytical laboratory providing services to the pharmaceutical and biotechnology industries. Andrew is considered an expert in Laboratory Information Management (LIMS), Electronic Notebook, 21 CFR Part 11, and Life Sciences Content Management technologies and is a frequent speaker at pharmaceutical industry conferences and symposiums.

W. SCOTT HARKONEN, M.D., President, CEO, and Chairman of the Board of Directors, InterMune, Inc.

Dr. Harkonen founded InterMune in February 1998 and has served as a member of our board of directors since inception and our Chairman of the Board since January 2000. Dr. Harkonen has been our Chief Executive Officer and President since inception. From September 1995 to April 1999, Dr. Harkonen served as Senior Vice President of Product Development and Operations at Connetics Corporation, a biopharmaceutical company. From March 1991 to September 1995, Dr. Harkonen served as Vice President of Medical and Regulatory Affairs at Univax Biologics, a biopharmaceutical company. Dr. Harkonen is a member of the board for the Emerging Companies Section Governing Board of the Biotechnology Industry Organization. Dr. Harkonen is a director of several private companies.

EDWARD W. HOLMES, M.D., Vice Chancellor, Dean, Health Sciences, UCSD School of Medicine

Dr. Holmes attended public secondary schools in Winona, Mississippi, received a Bachelor of Science degree from Washington and Lee University, and received a Doctor of Medicine degree from the University of Pennsylvania. He pursued internal medicine training at the Hospital of the University of Pennsylvania and Duke University Medical Center, serving as Chief Medical Resident at the later institution. Dr. Holmes was also appointed as a Howard Hughes Medical Investigator at Duke University and remained in HHMI for 13 years. He rose through the ranks to become the Chief of the Division of Endocrinology, Metabolism and Genetics and the James B. Wyngaarden Professor of Medicine at Duke University. Dr. Holmes was recruited to the University of Pennsylvania School of Medicine in 1991 to become the Chair of the Department of Medicine and the Frank Wister Thomas Professor of Medicine and Genetics. In 1997 he moved to Stanford University School of Medicine to become the Joseph Grant Professor in the School of Medicine, the Senior Associate Dean for Research, Vice President for Translational Medicine and Clinical Research, and Special Counselor to the President of the University on Biomedical Research. In January 1999, Dr. Homes returned to Duke University as the Dean of the School of Medicine, Vice Chancellor for Academic Affairs and the Walter Kempner Professor of Medicine and Genetics. Dr. Holmes was appointed to the Vice Chancellor for Health Sciences and Dean, the School of Medicine at the University of California, San Diego in the fall of 2000. Dr. Holmes has engaged in basic biomedical and clinical research throughout his academic career, holding continuous NIH funding since 1975, including a MERIT Award.

The Right Life Sciences Law Firm?

15 P Phosphorus	6 C Carbon	53 I Iodine			
26 Fe Iron	8 O Oxygen	71 Lu Lutetium	14 Si Silicon	13 Al Aluminum	79 Au Gold
	7 N Nitrogen		16 S Sulphur	30 Zn Zinc	22 Ti Titanium

Elemental.

119 GC Gray Cary

Life sciences legal issues can be extremely complex. Gray Cary's commitment to the life sciences makes your decision simple. Our Life Sciences Group consists of attorneys who understand clients' technologies, know and keep abreast of the latest developments in the industry and function as value-added strategic advisors. The right law firm? To many of the world's most exciting life sciences companies and research institutions, it's elemental. It's Gray Cary.

GRAYCARY. TECHNOLOGY'S LEGAL EDGE®

www.graycary.com

Not Certified by the Texas Board of Legal Specialization. No designation has been made by the Texas Board of Legal Specialization for a Certificate of Special Competence in this area.

San Francisco Seattle Washington, D.C.
San Diego
Sacramento
Palo Alto
Austin

GREG HOROWITT, Director, Corporate Connections, UCSD Connect

As the director of corporate connections, Greg Horowitt cultivates, develops, and maintains corporate partner relationships in the high-tech and life science business communities in the San Diego area. He is also co-developing business and operational strategies to grow the organization into a globally recognized leader of accelerated support services for high-tech start-up and mid-market companies. Greg moved down from the Bay Area in late 2001, where he served as an Entrepreneur-in-Residence for a leading Bay Area venture capital firm. Prior to that, he was president and CEO of The Praetorian Group, a venture backed enterprise software company providing e-business solutions to law enforcement and public safety agencies across the country.

CHUCK HOWE, Vice President, Sales, IDEC Pharmaceuticals Corporation

As the Vice President of Sales, Chuck Howe is responsible for the Field Sales Force, Customer Service, Sales Operations and Administration, Healthcare Economics and Reimbursement, as well as serving on the Executive Committee. He also works closely with Genentech, IDEC's partner with Rituxan, in developing strategies and tactics to maximize awareness and utilization by Health Care Professionals. Chuck came to IDEC 6 years ago to help develop the commercial area, which was new for IDEC. Chuck has held positions of increasing responsibilities in the Oncology and Biotech field for over 20 years.

GUY J. IANNUZZI, President, Mentus

Trained in both science and art and having held a variety of agency executive roles in San Diego and Los Angeles, Guy founded an agency, called Communication Design, in 1980. The company was a sole proprietorship, and became a corporation in 1983. The first clients were Aerojet, Linkabit and Hybritech. The agency changed its name to Mentus in 1986, in recognition of its specialization in high technology. Today Guy directs the strategic growth of the agency which is servicing clients focused in esoteric, breathtaking technologies that are defining the future of business and commerce.

SCOTT KAHN, Ph.D., Chief Science Officer and Senior Vice President, Research and Development, Accelrys

Scott Kahn directs scientific and product research and development at Accelrys, applying over a decade of experience in the computational chemistry industry. Previously a key figure in product development and marketing at BioCAD Inc. and Molecular Simulations Inc., Dr. Kahn has guided the commercial development of some of the world's most widely-used simulation products. He is a strategist and frequent conference speaker on topics relating to the use of information technology to enhance productivity in the discovery of new therapeutics. Dr. Kahn is himself an experienced software developer. His record includes involvement in the SPARTAN program, in developing analysis tools for medicinal chemistry research, and in the creation of a number of widely-used commercial modeling packages. Dr. Kahn received his Ph.D. in Theoretical Organic Chemistry from the University of California, Irvine, after which he did post-doctoral work at Cambridge University, UK.

FELIX A. KHIN-MAUNG-GYI, Pharm. D., M.B.A., CIP, CEO, Founder, Chesapeake Research Review, Inc.

In addition to heading Chesapeake Research Review, Inc., in early 2003, Dr. Gyi was appointed to the U.S. Secretary of Health and Human Services' Human Research Protections Advisory Committee (SACHRP). For twenty years, Dr. Khin-Maung-Gyi has provided consultation and professional development as well as managed research units, IRBs, and projects in both private and academic sectors. He has worked internationally, traveling and living abroad as well. Throughout his professional career, Dr. Gyi has also served on university faculty. Dr. Gyi received the Doctor of Pharmacy degree from Duquesne University; and the M.B.A. (Executive Program) from Loyola (MD) College. He was the first independent IRB representative to be certified as an IRB professional by the Council for Certification of IRB/IEC Professionals, Applied Research Ethics National Association (ARENA).

ARTHUR KLAUSNER, General Partner, Domain Associates

Mr. Klausner is a General Partner at Domain Associates, a venture capital firm specializing in early-stage life sciences investments. Klausner joined Domain in 1990 after earning an M.B.A. at the Stanford University Graduate School of Business. While attending business school, he completed summer internships emphasizing corporate planning and market research functions at ImClone Systems Corp. and Neurogen Corp., two start-up biopharmaceutical companies that have since gone public. Previously, Klausner had spent six years at Bio/Technology magazine (now Nature Biotechnology), where as Senior Editor he researched and prepared over 200 articles concerning scientific and business aspects of applied biology. He has also performed consulting projects for the U.S. Office of Technology Assessment, Arthur D. Little Decision Resources, and a variety of pharmaceutical and biotechnology companies.

DANA F. KOPPER, Senior Vice President, Marsh USA Inc.

Mr. Kopper is the FINPRO (Financial and Professional Services Group) Practice Leader for the Southern California operations of Marsh Newport Beach and San Diego. Mr. Kopper has provided a broad range of governance and risk management consulting / transactional services to public, private, for-profit, and not-for-profit organizations for the past 24 years – the past 12 years with Marsh. He is a noted expert in the areas of directors' and officers' legal liability, governance infrastructure design, corporate transparency, board effectiveness, director accountability, and associated risk mitigation strategies, including securities loss prevention, compliance efficacy and crisis management. From a transactional perspective, he is one of the top D&O brokers in the country, having structured more than 3,000 D&O insurance and risk financing programs, with particular emphasis in the manufacturing, technology, aerospace / defense, telecommunications, healthcare, biotechnology, and financial sectors.

DAVID MACK, Ph.D., Director, Alta Partners

David joined Alta in 2002. Prior to Alta, David co-founded and served as vice president of Genomics Research at Eos Biotechnology (which was acquired by Protein Design Labs in 2003). From 1996 to 1998, David served at Affymetrix as Head of Cancer Biology where he oversaw the development and application of DNA array technology in the areas of oncology and inflammation. David was also a pivotal member of the Polymerase Chain Reaction (PCR) invention group at Cetus (now Chiron) in the mid 1980s. David holds a Bachelor of Arts in Molecular Biology from University of California, Berkeley. His scientific background includes a post-doctoral fellowship at Stanford University School of Medicine in Microbiology and Immunology as an American Cancer Society fellow. David received his Ph.D. in 1992 from the University of Chicago where he was a Howard Hughes fellow in Molecular Genetics and Cell Biology.

Boston
Brussels
Chicago
Frankfurt
Hamburg
Hong Kong
London
Los Angeles
Milan
Moscow
New Jersey
New York
Northern Virginia
Orange County
Paris
San Diego
San Francisco
Silicon Valley
Singapore
Tokyo
Washington, D.C.

LATHAM & WATKINS LLP

Downtown San Diego Office
701 B Street, Suite 2100
San Diego, CA 92101
(619) 236-1234

North San Diego Office
12636 High Bluff Drive, Suite 300
San Diego, CA 92130
(858) 523-5400

is proud to support

CALBIOsummit 2003

Latham & Watkins attorneys address the entire spectrum of life sciences, pharmaceutical and biotechnology issues. We regularly represent all types of companies, from start-ups to multinational conglomerates, as well as the investment banks, lenders and venture capital firms that serve them.

www.lw.com

JOHN MARCHICA, Founder and CEO, FaxWatch Inc.

Since 1994, FaxWatch Inc., a Scottsdale-based medical news and information company, has been named twice to the Inc. 500 list of America's fastest-growing companies. Marchica is also a two-time finalist for the Ernst & Young Entrepreneur of the Year award. His first book, The Accountable Organization to be published in Fall 2003 by Davies – Black Publishing, is a call to action for transforming the business environment through the individual commitment of corporate citizens. Marchica holds a B.A. in economics from Knox College, an M.A. in public policy from the University of Chicago and an M.B.A. from the University of Chicago.

MARTIN MATTINGLY, Vice President and General Manager, Agouron

Martin Mattingly is VP, General Manager for the Agouron division of Pfizer in La Jolla. The Agouron division of Pfizer is responsible for HIV/ÀIDS products in both the U.S. and Canada. Martin started his career in the pharmaceutical industry in 1983 as a sales representative for Eli Lilly and Company. Martin had a 13-year career at Eli Lilly and Company where he held a variety of positions in sales, sales management, new product marketing for CNS products and brand management for human insulin. Martin was responsible for U.S. oncology marketing and the launch of the successful cancer drug Gemzar prior to joining Agouron Pharmaceuticals in 1986. As Marketing Director at Agouron, Martin led the successful launch of Agouron's leading protease inhibitor for the treatment of HIV/AIDS. After the Warner Lambert acquisition of Agouron in 1999, Martin became Vice President, Global Marketing for the Agouron division of Warner Lambert responsible for oncology and anti-infectives where he remained after the Pfizer acquisition of Warner Lambert in 2000. In 2001 Martin became a Vice President in the Product Development Group at Pfizer's NY headquarters responsible for Pfizer's Phase 3 Global Development Teams, as well as the Portfolio and Decision Analysis group. Martin assumed the leadership of the Agouron division in May of 2002.

J. CASEY McGLYNN, Partner, Wilson Sonsini Goodrich & Rosati

J. Casey McGlynn is a WSGR partner and heads one of the largest new venture practices at the firm. He is a nationally recognized leader in the representation of startup and emerging growth technology companies. Mr. McGlynn's practice focuses on the organization, funding and corporate representation of companies in the information technology and life sciences industries. Mr. McGlynn assists emerging growth companies to meet their financing needs through introductions to an extensive network of angel investors, financiers, venture capitalists, corporate partners and investment bankers. As a strategic business partner, Mr. McGlynn and his group offer focused resources and capabilities to meet the most critical needs of startup and emerging growth companies, including private and venture capital financings; public offering; university licensing and strategic collaborations.

PHIL McHALE, D.Phil., Vice President of Corporate Communications & Scientific Affairs at MDL Information Systems, Inc

Phil McHale is VP of Corporate Communications & Scientific Affairs at MDL Information Systems, Inc., based in their San Leandro, CA headquarters. He has a D.Phil. in organic chemistry from the University of Oxford, England, and has over thirty years experience in the informatics industry as a producer, a consumer, and a vendor. He has worked for the Chemical Society (London), Wellcome, Pergamon, and Derwent Information. Since joining MDL in 1988, he has held a variety of positions in product planning and marketing, and assumed his current position in 2002.

ALAN C. MENDELSON, Partner, Latham & Watkins

Co-Chair of the Venture & Technology Practice Group and a partner in the Silicon Valley office, Alan's practice targeted toward emerging and public growth companies, with strong emphasis on companies in the life sciences industry. Alan is on the board of directors of several biotechnology and software companies and has handled major business transactions, including venture capital financings, private placements and public offerings, mergers and acquisitions, joint ventures and other strategic collaborations, R&D limited partnerships and commercial transactions.

STEVEN J. MENTO, Ph.D., President, CEO and member of Board of Directors, Idun Pharmaceuticals

From 1982 to 1992, Dr. Mento held various positions in viral vaccine research and development at American Cyanamid Company. His last position was Director of Viral Vaccine Research and Development from 1990 to 1992 at Lederle-Praxis Biologicals, a business unit of American Cyanamid Company. He joined Viagene, Inc. in January of 1992 as Vice President of Research and Development and held that position through October of 1995. At that time, Chiron Corporation acquired Viagene, Inc. and renamed the company Chiron Viagene. Dr. Mento was named President of Chiron Viagene and Vice President of Chiron Corporation. Chiron Viagene changed its name to Chiron Technologies-Center for Gene Therapy in November of 1996. Dr. Mento remained president until he left Chiron to join Idun in August of 1997. Dr. Mento serves on the following Boards of Directors: BIO Emerging Companies, BIOCOM, UCSD Healthcare Bannister Family House and UCSD Biological Sciences Board of Advisors.

WALTER H. MOOS, Ph.D., Chairman and CEO, MitoKor

Walter H. Moos, Ph.D., joined MitoKor as Chairman and Chief Executive Officer in January 1997. From October 1991 to January 1997, he was employed at Chiron Corporation where he was an executive officer, and last held the position of Vice President of Research and Development in the Technologies Division. From 1982 to 1991, Dr. Moos held several positions at the Parke-Davis Pharmaceuticals Research Division of the Warner-Lambert Company, last holding the position of Vice President, Neuroscience and Biological Chemistry. In addition to serving as Chairman of the MitoKor board of directors, Dr. Moos currently serves on the boards of directors of Rigel, the Biotechnology Industry Organization, and Keystone Symposia, and has previously served on the boards of Axiom, Mimotopes, and Onyx. He has edited several books, helped to found multiple journals, and has published over 100 manuscripts and patents. In addition, Dr. Moos has held adjunct faculty positions at the University of Michigan, Ann Arbor, and the University of California, San Francisco, and currently serves on several academic and related advisory committees. Dr. Moos holds an A.B. from Harvard University and received his Ph.D. in chemistry from the University of California at Berkeley in 1982.

The ambulance took a risk transporting the pregnant woman.

The hospital took a risk admitting the pregnant woman.

The manufacturer took a risk developing diagnostic equipment for the pregnant woman.

The ob-gyn took a risk attending to the pregnant woman.

The pharmaceutical firm took a risk producing fertility drugs for the pregnant woman.

And Marsh solved all these risks.

Marsh & McLennan Companies

www.marsh.com

MARSH

The world's #1 risk specialist

4445 Eastgate Mall, Suite 300
San Diego, CA 92121
858.552.4200

CHRISTIAN W. NOLET, Partner, Ernst & Young

Chris Nolet is a partner with Ernst & Young in Palo Alto, California and the leader of our Life Sciences Industry Services Group in the Pacific Northwest Area. Chris serves a number of the firm's premier clients, including Genentech, CV Therapeutics and Affymetrix. In addition, he supports E&Y engagement teams and life sciences clients throughout California and the western United States as a member of the Americas Life Science Industry Group Leadership Team. Chris has more than 22 years of experience serving life sciences companies, ranging from start-ups to large multinationals. He has participated in numerous private and public equity offerings and provided due diligence, valuation, structuring and execution leadership in connection with mergers, acquisitions, and collaborations.

ROBERT W. OVERALL, Ph.D., General Partner, Frazier Healthcare Ventures

He focuses primarily on company formation and seed/early stage venture investing in the biotechnology sector. He has played a key role in the founding and/or growth of several successful early stage biotechnology companies, including ActivX, Inc., Array BioPharma, Inc. and XenoPort, Inc. He obtained his Ph.D. from the Institute of Cancer Research, University of London, UK, and moved to Immunex in 1984, where he led research groups in the cell and molecular biology of novel cytokines and receptors. In 1988 he formed and led the gene therapy program at Immunex, which resulted in the first HIV gene therapy clinical trial in the world and formed the foundation for Targeted Genetics, which was spun out of Immunex in 1992. Dr. Overell joined Frazier in 1996. Together with the Frazier Healthcare team, he has participated in raising over $600M of venture funds for Frazier Healthcare III and IV.

FRANK J. PAPATHEOFANIS, M.D., MPH, Ph.D., President and CEO, Aequitas Consulting Group

Among his payer-related appointments, he is currently the Chairman, Diagnostic Imaging Panel, Medicare Coverage Advisory Committee (MCAC) of CMS (formerly HCFA) as well as a member of the Executive Committee of the MCAC. Dr. Papatheofanis maintains clinical and research responsibilities as Associate Adjunct Professor of Radiology, The Institute for Biomedical Engineering, and the NCI Comprehensive Cancer Center, all at UCSD. Dr. Papatheofanis has over 160 publications that are frequently cited in the professional literature, and serves as Editor in Chief of BMC Health Technology Assessment and Policy, Associate Editor of IEEE Bioengineering in Medicine and Biology and Statistics Editor of the Journal of Vascular and Interventional Radiology.

B. LYNNE PARSHALL, J.D., Executive Vice President and CFO, Isis Pharmaceuticals, Inc.

Lynne Parshall is Executive Vice President, CFO and a Director at Isis Pharmaceuticals. She is responsible for manufacturing, business development, finance and the company's legal and patent affairs. Previously, Parshall was a Partner with the firm of Cooley Godward LLP where she represented a significant number of large and small health care companies in a general practice specializing in corporate partnering and other technology-based transactions. Parshall received her J.D. at Standford Law School in 1979 and her B.A. from Harvard University in 1976.

CARL C. PECK, M.D., Professor of Pharmacology and Medicine; Director, Center for Drug Development Science, Georgetown University Medical Center

Dr. Peck joined the FDA as Director of Center for Drug Evaluation and Research in October 1987. He was promoted to Assistant Surgeon General in the Public Health Service in October 1990. Retiring from the FDA in late 1993, Dr. Peck was appointed "Boerhaave" Professor of Clinical Drug Research at Leiden University in The Netherlands. In 1994, Professor Peck joined the faculty of the Georgetown University Medical Center, where he is the founding Director of the Center for Drug Development Science. In 1999, Commissioner Henney presented Dr. Peck with the FDA Distinguished Alumnus Award. Sweden's University of Uppsala conferred an honorary doctorate degree to Dr. Peck in January 2002 in recognition of "outstanding contributions to the science of drug development."

VIJAY PILLAI, Director Life Sciences, Oracle

Vijay Pillai is responsible for Oracle Life Sciences industry strategy with a focus on Discovery. He has been instrumental in developing and promoting bio-analytical computing, processing and data management standards adopted worldwide. Having lead the Celera Genomics team for Oracle for three years during its crucial phase of sequencing and assembling the human genome, Mr. Pillai is intimately familiar with some of the most monumental scientific databases ever created. Recently he has been spending time at NIH looking into patterns in microarray data sets. Vijay's background has been in high performance architectures for large databases in the multi terabyte range for both storage and computing.

JACK W. REICH, Ph.D., Founder and Former CEO, Collateral Therapeutics

Dr. Reich was most recently the CEO and Chairman of the Board for Collateral Therapeutics, Inc. prior to its July 2002 acquisition by Schering AG. The company is a leader in the field of cardiovascular gene therapy and went public in July of 1998. Dr. Reich was also a general partner of Cabrillo Partners, a San Diego-based business development company created to develop start-up and early-stage companies focused in the areas of health-care, medicine, biotechnology and life sciences. Prior to forming Cabrillo Partners, Dr. Reich was Senior Vice President of Enterprise Partners, a successful, Southern California-based venture capital firm and has played a key role in developing biotech and medical technology companies. Prior to his career in venture capital, Dr. Reich was Vice President, Regulatory Affairs and Quality Operations at Gensia, Inc.

WILLIAM L. RESPESS, Vice President and General Counsel, Applied Molecular Evolution, Inc.

William Respess is Vice President and General Counsel of Applied Molecular Evolution, Inc. of San Diego, California, a biotechnology company engaged in the application of techniques of directed molecular evolution to the development and optimization of human biotherapeutic proteins.

DIANE ROMZA-KUTZ, Partner, Mayer, Brown, Rowe & Maw

Diane Romza-Kutz's experience includes the following: health care regulatory and litigation matters, including FDA matters, clinical trial contracting and risk assessment including informed consent issues, pharmaceutical pricing issues related to AWP and Medicaid Rebates, structuring and implementing compliance plans, corporate and managed care contracting, fraud and abuse and the creation of provider networks and related administrative

CREATIVE LOGIC. IT DOES EXIST.

Branding

Advertising

Sales Support

Environmental

Online

Annual Reports

Public Relations

When you connect the right side of the brain with the left, wonderful things happen. At Mentus, you will find a group of dedicated communications and marketing specialists who cross-pollinate disciplines to develop sound, creative solutions that appeal to all the senses.

mentus

San Diego, CA
www.mentus.com
858.455.5500

and management agreements, administrative and litigation expertise, civil and criminal health care matters including advising and defending clients on false claims and qui tam matters and managed care contracting work for insurers, hospital networks, physicians and other providers, and litigating health care claims arising from regulatory, managed care or other related areas.

R. MICHAEL SCARANO, JR., Partner in Health Law Department, Foley & Lardner

R. Michael Scarano, Jr. is a partner in the Health Law Department of Foley & Lardner. He is a member of the Compliance/Payments Practice Group. Scarano has represented a wide variety of health care clients. His primary areas of practice include fraud and abuse/compliance, managed care, allied health professions, EMS law and general business transactions such as entity formation and sales/acquisitions. Scarano is a 1984 graduate of Boalt Hall School of Law at the University of California at Berkeley, where he was an associate editor of the Ecology Law Quarterly. He received his Bachelor of Arts degree, with academic distinction, from the University of California at Berkeley in 1978.

JOHN A. SCARLETT, M.D., President and CEO of Tercica Medica, Inc.

Dr. Scarlett is the President and CEO of Tercica Medica Inc., a San Francisco biotechnology company, which has acquired the rights to Insulin-Like Growth Factor-I (IGF-I) from Genetech, Inc. Dr. Scartlett was previously the founder and Chief Executive Officer of Sensus Drug Development Corporation from the company's inception in 1993 until its acquisition by Pharmacia, Inc. in March 2001. Dr. Scarlett also co-founded Covance Biotechnology Services, Inc. (CBSI), a leading contract biomanufacturing organization located in Research Triangle Park, NC. Dr. Scarlett is an honors graduate of Earlham College and received his M.D. with honors from University of Chicago Pritzker School of Medicine.

DREW SENYEI, M.D., Managing Director and General Partner, Enterprise Partners Venture Capital

Drew joined Enterprise Partners in 1988 and has been the lead managing member for most of Enterprise Partners medical technology companies including the following public companies: Ligand Pharmaceuticals, Corixa Corporation, Sonus Pharmaceuticals, Nanogen Incorporated and Discovery Partners International, Inc. . Drew is currently the lead managing member on eight active portfolio companies. His investment activities have created substantial aggregate market capitalization values in excess of $2 billion. Prior to his fifteen years with Enterprise Partners, Drew developed a strong background in the basic sciences and is an inventor with over 30 U.S. and foreign patents and pending applications in a variety of fields. His inventions have helped form the basis of the core intellectual property of several Enterprise Partners portfolio companies including Discovery Partners, Adeza Biomedical and Genoptix.

DAVID SHAPIRO, M.D., ChB, CRCP FFPM, Executive Vice President and Chief Medical Officer, Idun Pharmaceuticals

Dr. Shapiro received his medical degree from Dundee University and Medical School in the U.K. He undertook further general medical and respiratory specialist training in the University Hospitals in Oxford and at the University of Vermont, where he was awarded a Fellowship from the American Heart Association. In recent years he formed a consulting company, Integrated Quality Resources, and has worked closely with several biotechnology, pharmaceutical and device companies. In late 2001, he joined Idun Pharmaceuticals as Executive Vice President of Medical Affairs and Chief Medical Officer.

LAWRENCE SOUZA, Ph.D., Managing Director, Coastview Capital, LLC

Previously Senior Vice President of Research at Amgen, Dr. Souza built a fully integrated genomics program with a scientific staff of more than 200, leading to one of the first products of the genomics era to enter clinical testing, osteoprotegerin. As a Director of Research at Amgen his department was responsible for the identification and characterization of the blockbuster drugs, EPOGEN and NEUPOGEN. In addition to discovering NEUPOGEN, Souza led the development of the program through the initiation phase III clinical testing.

LINDA G. STRAUSE, Ph.D., Global Clinical Project Advisor, CancerVax Corporation

Dr. Strause has worked as principal investigator for an international CRO, a SMO and currently as the Global Clinical Project Advisor for CancerVax Corporation. In that capacity she serves as liaison to clinical investigators and sites worldwide to prepare them for the ethical conduct of clinical trials in oncology. Her strong passion for ethical conduct of clinical studies began with her work on an international osteoporosis study, followed by her involvement at San Diego Hospice, which included serving as chairperson of the IRB and member on the Bioethics Board. Dr. Strause has been an invited speaker at the number of clinical research conference and is widely published, both in the field of clinical research conduct and in nutrition and calcium metabolism.

RUTH SUTER, Vice President and Senior Analyst, Acumen Sciences

Suter's responsibilities focus on identifying and communicating key reimbursement and pricing issues and best practices to Acumen's clients as well as applying reimbursement, pricing and managed care-related insights to other Acumen product offerings. Suter has over 15 years of experience in pharmaceutical product and health care services marketing, sales and management. Her skills include managed care and reimbursement strategy development and execution. For the past 10 years, she has worked in the biopharmaceutical and pharmaceutical arenas, building business planning and product commercialization expertise from early stage clinical development, through launch and product maturity. Experience Includes: Director, Managed Care Strategy & Policy, Genentech, Inc.; National Healthcare Consultant, Pfizer, Inc.; Regional Manager, HMO Health Services, Blue Shield of California.

MICHAEL SWIT, Esq., Special Counsel, Heller Ehrman

Michael Swit joined the San Diego office of Heller Ehrman in May 2001 as a Special Counsel. He is a member of the firm's FDA Group, which is within the Life Sciences National Practice Group. Mr. Swit has extensive experience in all aspects of FDA regulation with a particular emphasis on drugs and medical device law and regulation. In addition to his private FDA regulatory law experience, Mr. Swit also served for three and a half years as vice president and general counsel of Pharmaceutical Resources, Inc. (PRI), a prominent generic drug company and, thus, also brings an industry and commercial perspective to his representation of FDA-regulated companies.

NANDINI TANDON, Ph.D., Partner, Life Sciences Venture Fund, RBC Capital Partners

Nandini Tandon, Ph.D. is a Partner, Life Sciences Venture Fund, RBC Capital Partners. Dr. Tandon has over a decade of experience in successfully developing and commercializing scientific technologies in three high-tech industries: biotechnology, pharmaceuticals and semiconductors. Dr. Tandon's experience encompasses strategic alliances, licensing, research partnerships, marketing and corporate communications, as Chief Business Officer, Zyomyx, V.P. Corporate Development and Corporate Communications, Hyseq Inc. and various positions held in business development, marketing and research at Chiron, Glaxo and Microelectronic Center respectively. A White House Intern and a Phi Beta Kappa, Dr. Tandon received her doctorate in Biochemistry from Duke University.

MARK R. VAN AUSDAL, Counsel, Mayer, Brown, Rowe & Maw

Mark R. Van Ausdal has extensive international experience in acquisitions and divestitures, joint ventures, co-promotion and licensing arrangements, and general commercial and corporate matters. Prior to joining Mayer, Brown, Rowe & Maw, he held senior in-house counsel positions at Pharmacia Corporation (formerly Monsanto Company) and G.D. Searle & Co. Mark was the principal drafter and legal representative in developing a co-promotion agreement with a U.S. pharmaceutical company which has yielded more than $4 billion in sales. He negotiated a $300 million research agreement with a Japanese pharmaceutical company, negotiated the sales and purchases of over 100 businesses or products, and developed joint venture agreements in Italy, Japan, Korea, Taiwan, and the U.S.

MARY JO VEVERKA, Life Sciences Partner, Accenture

Ms. Veverka is affiliated with the Health and Life Sciences Practice of Accenture. She has over 20 years of management consulting experience, predominantly with pharmaceutical, biotechnology and medical product companies and has led Accenture's R&D and Regulatory Excellence programs. She has authored numerous publications addressing the challenges facing R&D and Regulatory leadership. Prior to joining Accenture, Ms. Veverka was the Deputy Commissioner for Management and Systems with the U.S. Food and Drug Administration. While at the FDA, she led the negotiation and implementation of the Prescription Drug User Fee Act of 1992 and also oversaw many other areas of operational improvement. She recently supported BIO and PhRMA in the reauthorization of PDUFA II. Prior to joining the FDA, Ms. Veverka was a Vice President, Head of the Worldwide Pharmaceutical Practice at a leading strategy consulting firm.

JOHN P. WALKER, Chairman and CEO, Bayhill Therapeutics, Inc.

John P. Walker is currently Chairman and Chief Executive Officer of Bayhill Therapeutics, Incorporated. Prior to joining Bayhill in October 2002 he was a Venture Partner with Morgan Stanley Venture Partners and as an independent consultant was Chairman and Interim CEO of Centaur Pharmaceuticals whose assets were sold to Renovis, Inc. From 1993 to 2001 he was Chairman, Chief Executive Officer and a Director of Axys Pharmaceuticals Inc. and its' predecessor company Arris Pharmaceutical. Axys was merged into Celera Genomics at the end of 2001. Prior to his association with Arris, Mr. Walker was the Chairman and Chief Executive Officer of Vitaphore Corporation, a biomaterials company that was sold to Union Carbide Chemicals and Plastics Company Inc., in 1990. Mr. Walker is currently a Director of Geron Corporation, Discovery Partners International Inc. and certain other privately held biotechnology companies.

SHIRLI FABBRI WEISS, Partner, Gray Cary Ware & Freidenrich

Shirli Weiss is a partner at Gray Cary Ware & Freidenrich and has specialized in defending public Companies and directors and officers in securities litigation for more than 25 years. She has successfully defended numerous shareholder actions in federal and state court and SEC proceedings. She was lead counsel in In re the Vantive Corporation Securities Litigation, recognized as one of the top ten defense victories in 2000 by the Los Angeles and San Francisco Daily Chronicles.

KENNETH J. WIDDER, M.D., General Partner, Windamere Venture Partners

Kenneth Widder, a General Partner at Windamere Venture Partners, founded, chaired and was CEO of Molecular Biosystems, Inc. until 1998. He is Chairman of the RTA-San Diego and serves as a director of BIOCOM. He is on the Board of Directors for FeRx Inc., Converge Medical, Inc., NovaCardia and is chairman of Santarus, Inc. Previous Boards that he has served on include Titan Pharmaceuticals, Inc., DigiVision, Inc., Wilshire Technologies, Inc., California Healthcare Institute, UCSD Cancer Center Foundation and Carleton College. He authored and co-authored numerous scientific publications and is an inventor on 15 patents. He received his Bachelor's degree from Carleton College in 1974 and his Medical Degree from Northwestern University in 1979.

RANDALL E. WOODS, President and Chief Executive Officer, Corvas International

Mr. Woods has served as President, Chief Executive Officer and a director of Corvas International, Inc. since 1996. From 1994 to 1996, Mr. Woods was President of Boehringer Manheim's United States pharmaceutical operations and, prior to that office, was Vice President of Marketing and Sales. Mr. Woods began his career in the pharmaceutical industry at Eli Lilly & Company where he served in various sales and marketing capacities between 1973 and 1993. Mr. Woods holds an M.B.A. from Western Michigan University and a B.S. in Biology/Chemistry from Ball State University.

GERALD J. YAKATAN, Ph.D., President and CEO, Avanir Pharmaceuticals

Dr. Gerald J. Yakatan has been President and CEO of Avanir Pharmaceuticals since March 1998. Dr. Yakatan also serves as Chairman of IriSys Inc., a company he founded in 1996 that specializes in pharmaceutical product development contract services. In 1990, he founded Tanabe Research Laboratories, USA, Inc., where he served as president and CEO for five years. From 1987-90, Dr. Yakatan served as Executive V.P. for R&D at Immunetech Pharmaceuticals. From 1980-82, Dr. Yakatan was employed at Warner-Lambert where he was ultimately V.P. for worldwide product development.

MICHAEL ZIERING, President and CEO, Diagnostic Products Corporation

Michael Ziering currently serves as the President and CEO of Diagnostic Products Corporation, a medical manufacturer that employs over 650 people in Los Angeles and 1,800 worldwide.

Workshop Speakers

LINDA E. AMUSO, Principal, iQuantic-Buck, Inc.

Linda E. Amuso is a highly recognized expert in the field of executive and general compensation design for the high-tech and life sciences sectors at all stages of company development. Her range of experience includes performance management and measurement, salary management systems, sales force management, annual and stock option incentive plan design, and Board compensation across numerous industry sectors, including financial services and manufacturing. In addition, she has experience in the design and implementation of human resources systems, including: organizational and job design, process reengineering, organizational change, and implementation support.

KENNON W. BALDWIN, AIA, President, McGraw/Baldwin Architects Inc.

Kennon Baldwin has served as Principal-in-Charge for a broad range of projects for such clients as Alexion Pharmaceuticals, IDEC Pharmaceuticals, Cancervax, The Burnham Institute, UCSD, Ligand Pharmaceuticals, Cymer, Nokia, Advanced Tissue Sciences, Viagene, and Cell Genesys. He is an executive board member of the San Diego Biocommerce Association (BIOCOM), founded by his late partner James McGraw; a member of the University of California San Diego, Program in Technology and Entrepreneurship (CONNECT); the American Institute of Architects (AIA); and the International Society for Pharmaceuticals Engineers (ISPE).

LEE BRUNO, Technology Editor, Red Herring

Lee Bruno is Technology Editor at Red Herring magazine and writes an online column called Lab Rat twice a month that reports on the most compelling research and development taking place in large and small corporate labs and prestigious universities. He has been reporting and writing about technology for the past 14 years. Prior to joining Red Herring in November 1999, he was a senior editor covering networking technologies at Data Communications magazine. He has appeared on CNN and radio programs, providing commentary on technology and business issues. Mr. Bruno graduated with a bachelor's degree in biology from San Francisco State University and received a master's degree in journalism from Boston University.

CARIN C. CANALE, Vice President, Atkins + Associates

Carin has more than ten years of extensive experience in public relations, media relations and corporate positioning. Prior to joining Atkins + Associates in January 2001 to spearhead the public relations division of the agency, Carin worked for The Townsend Agency, San Diego's largest integrated marketing firm, where she managed national and international high-technology accounts. Carin's experience includes launching more than thirty new companies, products and services in the biotechnology and high technology sectors; conducting market research; crisis communications, generating trade and business press; and helping companies to establish corporate positioning and target markets.

FRED CARMODY, President, Biostruct Sources Inc.

Fred Carmody provides organizational leadership for Biostruct Inc. Specifically, he has responsibilities in a variety of areas including acting as principal in charge on construction projects, technical consultant to project personnel including architects and MEP contractors, mechanical coordinator on construction projects, etc. Mr. Carmody has been in the construction industry since 1985. Mr. Carmody co-founded Biostruct, Inc. in 1995. He previously served as a biotech facility manager for 6 years for Gensia Pharmaceuticals, Inc., and as a biotech facility technician for 4 years at Hybritech, Inc. Mr. Carmody has been involved in the design and construction of approx. 800,000 square feet of biotech research and development space.

KAREN CHURCH, R.A.C., Vice President of Regulatory Affairs, La Jolla Pharmaceutical Company

Ms. Church joined the Company in 2002 as Vice President of Regulatory Affairs. She has held regulatory positions with Ancile Pharmaceuticals, Inc., Gensia, Inc. (now Sicor, Inc.), Neurocrine Biosciences, Inc., InSite Vision, Inc., Hoffman La Roche, Abbott Laboratories and Astra Pharmaceutical Products (now AstraZeneca, PLC). She has worked with the Center for Drug Evaluation and Research, including the Cardio-Renal Division, the Center for Biologics Evaluation and Research and the European Agency for the Evaluation of Medicinal Products. She has worked with product candidates in therapeutic areas such as cardiology, nephrology, immunology, oncology, neurology, metabolic endocrinology, anti-inflammatory, anti-infective, pulmonary, urology, and dermatology.

JIM CONSTANTINE, Senior IT Architect, Sun Microsystems

Jim Constantine has well over 20 years of Systems Engineering and IT Architecture and design experience. He has worked on very large IT infrastructure projects with Daimler-Chrysler, AT&T, Genentech, and Plexxikon to name but a few. Jim utilizes his extensiveIT Arhitectural background to bring a wealth of insight and experience to the Life Sciences industry.

DIANA DE WALT, President, The HR Company

With over 20 years experience in human resources, Diana De Walt, president and principal consultant, founded The HR Company in 1993 and has provided professional human resources services to more than 55 companies in a wide variety of industries. Her clients have included high tech, biotech, medical device, food services, non-profit and manufacturing, ranging in size from 10 employees to more than 500, and having offices in California as well as many other states. She has managed consultants working on a wide variety of projects ranging from establishing the human resources function for start-up companies to guiding the organizational restructure of more mature organizations.

DENNIS T. FERGUSON, Director of Human Resources, Stratagene

Dennis Ferguson is responsible for Stratagene's human resource activities worldwide. Prior to joining Stratagene, Mr. Ferguson was with Baxter Healthcare Corporation, Hyland Immuno division, a leading plasma fractionation manufacturer, where he was responsible for the company's human resource, security, training and environmental health & safety functions. He has previously held human resource management positions at Greenfield Environmental and Chemi-Tronics Inc. Mr. Ferguson holds a B.S. degree in business administration from California State University at Los Angeles, and a certificate in personnel management from the University of California, San Diego.

JAMES T. FERGUSON, Vice President, McGraw/Baldwin Architects

James Ferguson, Vice President of the San Diego-based architecture, planning and interior design firm McGraw/Baldwin Architects (M/BA) began his career as a designer and apprentice carpenter for a development company in Wisconsin. Jim graduated with honors and received his Bachelor of Science and Bachelor of Architecture degrees from North Dakota State University in 1985, where he also was employed as a Teaching Assistant during his senior year. Immediately after graduating, Jim moved west to San Diego and was employed by the development company of Jackson & Associates. In 1987 Jim joined McGraw/Baldwin Architects to officially start his professional career. Two years later he received his California architectural license and was promoted to Project Architect and Associate. In 1991 he became Project Manager and Senior Associate with the firm. After many successful and profitable projects Jim was offered and took a Principal position with M/BA.

STANDISH FLEMING, Managing Member, Forward Ventures

A 16-year veteran of the early stage investing, Standish Fleming co-founded Forward as a venture capital investment firm and serves as the president and chief executive officer of Forward Ventures Services Corporation ("FVSC"). Throughout his career at Forward, Fleming has served as acting president of Triangle Pharmaceuticals, Actigen (now Corixa), GenQuest (now Corixa) and CombiChem (now DuPont Pharmaceuticals). He was a founding board member of Ciphergen Biosystems and Gryphon Sciences. Mr. Fleming is a former president of the Biotechnology Venture Investors' Group ("BVIG"). He now serves as a director of Aventa Biosciences Corporation, Converge Medical, EndiCOR, MitoKor, Sanarus Medical, Tandem Medical, and is a founding director of Arizeke Pharmaceuticals, Nereus Pharmaceuticals and Triangle Pharmaceuticals. Fleming earned his B.A. from Amherst College and M.B.A. from the UCLA Graduate School of Management.

GLEN PAUL FREIBERG, R.A.C, Vice President, Regulatory, Quality & Government Affairs, Gen-Probe, Inc.

Glen Freiberg joined Gen-Probe in April 1998. He is currently Vice President - Regulatory, Quality & Government Affairs and a member of the firm's Executive Committee. Prior to joining Gen-Probe, Mr. Freiberg was the Vice President of Regulatory Affairs, Quality Systems and Clinical Affairs at Bard Diagnostics. His background includes working at the FDA as an Investigator in the Boston District. He has held industry positions in areas regulated by the three FDA Centers covering Drugs, Biologics and Medical Devices and has served three terms as the Industry Representative on FDA Advisory Panels, first for Clinical Chemistry/Toxicology and then Immunology.

FARIBA F. GHODSIAN, Ph.D., Managing Member, Director of Research, Castle Creek Lifescience Partners LLC

Fariba Ghodsian is currently Managing Member at CCL Partners, an $85 million hedge fund, where she oversees the fund's research team. Prior to that, she was Managing Director and Head of Healthcare Research at Roth Capital Partners. Since 1994, she has worked as senior biotechnology analyst at Lehman Brothers, Hancock Institutional (Sutro/Tucker Anthony) and Wedbush Morgan Securities. In 2002, Dr. Ghodsian was ranked among the top five biotechnology analysts in the Wall Street Journal's "Best on the Street" survey. Dr. Ghodsian has also held positions of scientist, director of business development and board member for several biotechnology companies. She received her M.B.A. from UCLA, postdoctoral fellowship from Harvard Medical School, Ph.D. in Biomedical Engineering from Oxford University, M.S. in Chemical Engineering from MIT, and B.S. in Chemical Engineering from Technion, Israel Institute of Technology.

MARTY GLICK, Executive Vice President and Chief Financial Officer, Theravance, Inc.

Marty is the Executive Vice President and CFO at Theravance which is a progressive, emerging pharmaceutical company led by an experienced management team in tandem with an outstanding Board of Directors. Marty has over thirty years of business experience including ten years with Genentech where he ended his tenure as Vice President of Finance. He worked for a combined fifteen years with Arthur Andersen & Co. and Levi Strauss & Co., including seven years in Canada and England. He has an M.B.A. in Finance from the Kellogg School of Management at Northwestern University. Mr. Glick is also a Certified Public Accountant and a Chartered Accountant (Canada).

DAVID F. HALE, President and CEO, CancerVax Corporation

David Hale has had a significant career in the biotechnology industry. After joining Hybritech, Inc., the first monoclonal antibody company, as Sr. VP Marketing and Business Development in 1982, he became Chief Operating Officer in late 1982, President in 1983 and CEO in 1986, when Hybritech was acquired by Eli Lilly and Co. He served from 1987 to 1997 as Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor (now Sicor, Inc.) and he was founder and Chairman of Viagene, Inc. from 1987 to 1994, when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc. from Jan 1998 to June 2000, prior to joining CancerVax in October 2000. Prior to joining Hybritech, Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co.

BRENT JACOBS, Senior Vice President, Burnham Real Estate Services

With over 20 years experience with biomedical facilities, Brent has authored several articles on biomedical real estate and lectured on the subject. Brent is a founder of BIOCOM, a biomedical industry consultant's organization, where he co-chairs the Facilities Committee. Brent also co-chairs the Life Science Division of ONCOR International. Brent's civic affiliations include the San Diego High Tech Museum. In addition, Brent is a trustee of the Reuben H. Fleet Science Center and a board member of La Jolla Institute for Molecular Medicine.

ERIC JOHNSON, Senior Systems Engineer, Sun Microsystems

Eric Johnson supports pre-sales systems architecture and design activities for Sun's Life Sciences group in San Diego. Eric holds a BSEE from DeVry Institute and has over 14 years of IT experience through various positions at LSI Logic, Sun Microsystems and Maui High Performance Computing Center.

BERNARD D. KING, M.D., M.B.A., President and CEO, Macnas Consulting International

Dr. King has over 15 years experience managing business and development operations in the pharmaceutical, medical device, biotechnology and CRO (Contract Research Organization) industries. Most recently, Dr. King was president and CEO of Predict, Inc., a New Jersey-based-bioinformatics company. Prior to joining Predict, Dr. King was Vice-President and General Manager for San Diego Operations for PAREXEL and Head of PAREXEL's Emerging Growth Opportunities Group; President and COO at Advanced Bioresearch Associates; EVP for Biological Sciences and Medical Affairs at Trega Biosciences (and President of ChromoXome after its acquisition by Trega); President of Segenix, a spinout of Advanced Tissue Sciences, where Dr. King had previously headed Research and Development; VP Worldwide Medical and Regulatory Affairs for ConvaTec, a BristolMyers Squibb subsidiary; and, Director of Clinical Investigation at SmithKline.

RUSSELL LEWIS, Reporter, KPBS News

Russell Lewis is KPBS's "Metro" beat reporter, covering issues such as biotech, transportation, and development projects including the downtown ballpark. Before coming to KPBS in 1999, Russell was the statehouse bureau chief for Kansas Public Radio and he has also filled in as a reporter and producer for National Public Radio in Washington, D.C. and has worked as a producer, reporter and anchor for WUFT in Gainesville, Florida and WSVH in Savannah, Georgia. Russell is a nationally recognized reporter. He has won more than a dozen awards, including six from the Associated Press and a first place award from Public Radio News Directors, Inc (PRNDI).

MAGDA MARQUET, Ph.D., Co-President and Co-CEO, Althea Technologies Inc.

Dr. Magda Marquet, a founder of Althea Technologies, has had over twenty years of experience in the biotechnology industry in the United States and Europe. She was formerly Executive Director of Pharmaceutical Development at Vical Incorporated, where she established herself as a leader in the production of clinical grade DNA for use in gene therapy and DNA vaccines. Prior to joining Vical, Dr. Marquet held process development positions at Amylin Pharmaceuticals, Protein Polymer Technologies, Syntro Corporation and Transgene. Dr. Marquet holds a Ph.D in Biochemical Engineering from the University of Toulouse/INSA.

LESLIE MARELL, Attorney, Law Office of Leslie S. Marell

Attorney Leslie Marell is established in private practice in Los Angeles and has more than 20 years experience counseling companies in commercial, contract, and technology law. For the past 10 years, Ms. Marell has presented seminars to thousands of purchasing professionals on purchasing and contract law. She has published many articles and co-authored "The Purchasing Handbook" (McGraw-Hill.) Ms. Marell is an informative and entertaining speaker who successfully converts "legal mumbo jumbo" into useful, understandable concepts.

LAUREL MARSHALL, Consultant

Laurel Marshall is an innovative, results-driven consultant, specializing in Organizational Effectiveness and Human Capital Solutions. Laurel has previously held internal senior-level leadership roles in Strategic Human Resources, with over 12 years of experience in entrepreneurial, fast paced, multinational businesses. Most recently, Laurel was the Global Director of Organizational Effectiveness for Johnson & Johnson Pharmaceutical Research and Development, LLC, where she led a globally based HR team, and was responsible for development, direction and implementation of HR strategy, globalization planning, alignment, integration and expansion of US and European Drug Discovery operations spanning 6 sites and 4 countries. Previously with J&J, she developed and managed start-up and rapid expansion activities for J&J's biotechnology research operation in San Diego.

RICHARD MEJIA, JR., Partner, Ernst & Young

Rich is the Director of Life Sciences practice in Southern California and has been in San Diego for 15 years. Rich services both public and emerging growth companies, primarily in life sciences. With more than 30 years at Ernst & Young, he has extensive experience with equity and debt offerings, international expansion, joint ventures, mergers and acquisitions, IPOs and securities transactions. Rich is a graduate of the University of Southern California and serves on the board of BioCom as well as the Executive Committee. He also serves on the board of the San Diego Venture Group.

GEORGE MILSTEIN, Managing Director, Pacific Growth Equities

George joined Pacific Growth in 1997 as a Managing Director in investment banking. Previously, he was in the investment banking group at Robertson, Stephens & Company where he focused on emerging growth technology investment banking. Prior to Robertson, he began his banking career with Pacific Growth in 1993 working with emerging growth companies primarily in technology and healthcare. George has also worked in the Corporate M&A group at Skadden, Arps, Slate, Meagher & Flom and was a legal fellow in the office of Senator John McCain of Arizona. He received his B.S. in Biology from the University of Southern California and his J.D. from the University of Arizona.

KRISTEN PHILIPKOSKI, Reporter, Wired News

Kristen Philipkoski covers life science technologies for Wired News, including gene and genome analysis, gene therapy, genetically modified crops, disease diagnosis and drugs. Before joining the staff, she was as freelance writer covering topics from ferrets to robot inventors for Wired magazine, Health, Life, Parenting and People. When not writing news, Kristen works on fiction and trains for marathons. Kristen is from Danville, Pennsylvania.

FRED PLEVIN, Managing Partner, Paul, Plevin, Sullivan & Connaughton

Mr. Plevin is the Managing Partner of Paul, Plevin, Sullivan & Connaughton, a San Diego-based law firm that was recently recognized by the Los Angeles Daily Journal as one of the top management-side labor and employment law firms in California. Mr. Plevin has specialized in the representation of California employers since 1986, and has defended employers in over 150 employment-related lawsuits. He is a frequent speaker and author on issues related to labor and employment law.

ANDY POLLACK, Biotechnology Writer, New York Times

Andy Pollack covers biotechnology for the New York Times, writing for the business and science sections. He has been with the Times since 1981, covering mainly business and high technology and working in New York, San Francisco, Tokyo and Los Angeles, where he is currently based. He has bachelor's and master's degrees in civil and environmental engineering.

RICK RAJECKI, Executive Consultant, Sun Microsystems

Rick Rajecki is an Executive Consultant for Sun Microsystems. He has lived and worked in Japan and numerous cities across the United States. He's worked for/with the FBI, Federal Reserve Bank, Sony Corporation, Warner and Swasey, among many others. He has a strong background as a CIO for a worldwide, non-profit, foundation. He draws upon his very diverse history and experience to architect complex IT solutions and infrastructures.

TEDDI REILLY, Vice President, Human Resources, La Jolla Pharmaceutical Company

She joined the company in 1998 as Director of Human Resources. From 1997 to 1998, she was Director of Human Resources at ThermoLase Corporation and from 1994 to 1997 at Solectek Corporation. Ms. Reilly has a BS in Psychology and has been a guest Human Resources presenter at BIO HR, UCSD, CBI, University of Phoenix, and others.

SHELLEY SIMMERMAN-ADDY, Director, Human Resources, MitoKor

Prior to being the Director of Human Resources at MitoKor, Shelley spent 20 years holding both HR and operational management positions in primarily entrepreneurial environments. Her article, "The Importance of Interviewing in Building a Successful Biotech (or Other) Company," was recently published in the journal DRUG DEVELOPMENT RESEARCH (Vol 57:103-105 [2002]). Ms. Addy received a B.A. in English/Writing from The Pennsylvania State University in 1981.

BRUCE STUMP, Partner, Ernst & Young

Bruce has 32 years of experience serving both privately and publicly held enterprises in the information technology, medical device, life sciences and manufacturing industries. Bruce also has extensive experience in SEC filings, mergers and acquisitions structuring, due diligence and business advisory services. Bruce is serving currently as the Ernst & Young Pacific Southwest Area Leader for implementation of Sarbanes Oxley and, in particular, Section 404 on Internal Controls. Bruce was the Southern California Area Director of Assurance and Advisory Business Services (AABS) from 1988 to 1995. He was also the Pacific Southwest Area Entrepreneurial Services AABS Industry Leader from 1998 to 2001.

MARIA C. WALKER, CPA, Chief Operating and Financial Officer, Forward Ventures

Maria Walker serves as the Chief Operating and Financial Officer at Forward Ventures, a $340 million venture capital firm investing exclusively in the life sciences. In addition to overseeing the venture operations at Forward, Maria also works closely with the firm's early stage companies providing operational support as they build their infrastructure. She has served as acting CFO to TargeGen and Kemia, two of Forward's early stage portfolio companies. Prior to joining Forward Ventures, Maria was a Senior Manager in KPMG's Healthcare and Life Sciences practice.

JAMES D. WATSON, Strategic Partnering Services, Burrill and Company

As a leader in the Strategic Partnering Services group, James Watson assists clients in the formulation and execution of business and corporate development transactions. Partnership structures include strategic collaborations, licensing of development and commercial stage assets, spin-outs and mergers and acquisitions. Prior to joining Burrill, Mr Watson held senior vice president positions with Incyte Genomics. His responsibilities included heading corporate and business development and leading the commercial and marketing organizations. Before joining Incyte, he was most recently General Manager and previously Vice President of Business Development for Chemdex, a Ventro Life Sciences Company. At Chemdex, Mr. Watson led the management team and over 100 employees of a pioneering, business to business marketplace for research scientists in biopharmaceutical and academic settings.

JOYCE H. WILLIAMS, R.A.C., Vice President, Drug Development, Arena Pharmaceuticals

Joyce Williams has served as our Vice President, Drug Development since February 1998. From January 1997 to February 1998, Ms. Williams served as Regulatory Consultant for ProFocus Regulatory Solutions. From 1995 to 1996, she served as Executive Director, Regulatory Affairs at Advanced Sterilization Products, a division of Johnson & Johnson. Ms. Williams has over 20 years of experience in regulatory affairs with pharmaceutical and medical technology firms. Ms. Williams holds a B.A. from Case Western Reserve University and an M.B.A. from Pepperdine University.

MARY YAROSHEVSKY-GLANVILLE, Senior Director, Human Capital, Anadys Pharmaceuticals Inc.

Mary Yaroshevsky-Glanville joined the Company from Inflazyme Inc., where she was their Director of HR. Previous positions include, Director of HR at Inex Pharmaceuticals, HR Manager at HBC Inc., Systems Engineer for EDS, and Co-Therapist for the Family Life Foundation. Mary has attended the Social Sciences Program at the University of Toronto, received a B.Sc. in CIS Management, and completed her Certificate in HR Management from BCIT. Mary also holds a CHRP designation.

MICHELE YELMENE, Executive Director of Clinical & Regulatory Affairs, Perlan Therapeutics

Michele Yelmene brings over 20 years of pharmaceutical and biotech experience to Perlan. She has extensive experience developing, conducting, and reporting Phase 1, 2, and 3 clinical studies for drugs, devices and biologics. In addition, she has prepared and directed 12 successful NDAs, BLAs, MAAs and PMAs. Her experience with the FDA spans a variety of disciplines including Critical Care/Anesthetics, Metobolic and Endocrine, Pulmonary, Neuropharmacology, Medical Imaging, Radiopharmaceutical and Biologics. Before joining Perlan, she was a director at Genzyme Corporation. Ms. Yelmene received her Bachelor of Science degree in Biology and Bachelor of Arts degree in English from Rider University. She is responsible for all aspects of the commercialization of ColdSol™ in addition to coordinating all of Perlan's operations.

Exhibitors

Company Name	Booth #
Advanced Clinical Services	405
Airgas	314
Alremarle Corporation	113
American Express Corporate Services	216
Arizona State University Research Park	114
Atkins + Associates	402
Atypon Systems	217
Avanir Pharmaceuticals	206
Aztec Business Machines	312
BACHEM Inc.	117
Becton Dickinson	315
BIOCOM	111
BioSpace	213
Biostruct	410
Biotechnology Industry Organization	412
Business Wire	415
California Manufacturing Technology Center	212
Celgene Corporation	211
ChemNavigator	205
Chubb Group of Insurance Companies	103
Clarus Energy Partners, L.P	116
Comerica – Technology and Life Sciences	301
Cooley Godward LLP	400
Deloitte & Touche LLP	401
EncorePharma Development Services, LLC	403
Fischer Scientific Company, L.L.C.	214
Foley & Lardner LLP	207
FourSquare	118
Gray Cary	101
Harlan	310
Heller Ehrman	201
Ingenix	219
Inland Empire Economic Partnership	106
Invest UK	419
Isis Pharmaceuticals, Inc.	302
Knobbe Martens Olson & Bear LLP	418
Lab Trader Scientific Equipment	203
Latham & Watkins LLP	300
LCS Constructors, Inc.	417
Marsh	200
Maxim Pharmaceuticals	202
Mentus	306
Mergen Ltd.	115
Morrison & Foerster LLP	413
Office Depot Business Services	318
Omnica Corporation	105
PaeTec Communications	313
Patheon Inc.	215
Prudential Cleanroom Services	319
San Diego Fluid System Technologies	414
San Diego Gas & Electric	407
San Diego Regional Economic Development Corporation	119
Scientific Software, Inc.	303
SignOnSanDiego.com	104
Silicon Valley Bank	107
Sun Microsystems	406
Tatum CFO Partners	218
Tetrionics, Inc.	416
The T-Sector	100
TIG	317
Transperfect Translations International, Inc.	304
UCSD Extension	102
VWR International	311
Wallace	316
Westland Insurance Brokers	204
Woodruff-Sawyer & Co.	210

* Exhibitor List as of February 19, 2003

Exhibit Hall Hours

Monday, March 10		5:30pm -7:00pm
Annual Dinner Reception		
Tuesday, March 11		10:30am -4:00pm
	Break	10:30am - 11:00am
	Break	3:30pm -4:00pm



Exhibitor Floor Plan



CALBIOsummit Staff and Steering Committee

BIOCOM Staff

Joseph Panetta
President & CEO

April Bailey
Director of Government Affairs

Timothy Biddle
Director of Business Development and Membership

Jennifer Landress, CMP
Director of Marketing and Events

Frounia Carroll
Purchasing Group Manager

Thomas Daglish
Community Relations Manager

DeLisa DeLeo
Accounting Manager

Lauri Fultz
Events and Marketing Manager

Jennifer Henry
Membership Manager

Melissa Guidi
Executive Assistant & Office Administrator

Katherine Hansen
Legislative Associate

Kathleen Roll
Coordinator, Educational Programs

Christine Scullion
Corporate Support/Front Desk

Shaye Testagrossa
Purchasing Group Assistant

Shyla Winter
Events Intern

Karen Wright
CALBIOsummit Assistant

CALBIOsummit Steering Committee

Howard Asher, Sun Microsystems

Susan Atkins, Atkins + Associates
Chair, Marketing Committee

Fred Cutler, UCSD CONNECT

Stephen Ferruolo, Heller Ehrman
Chair, Program Committee

Wain Fishburn, Cooley Godward LLP
Chair, Sponsorship Committee

Jeff Guise, Pillsbury Winthrop LLP
Chair, Program Committee

David Hale, CancerVax Corporation
Chair, Steering Committee

Guy Iannuzzi, Mentus
Chair, Sponsorship Committee

Paul Laikind, Metabasis Therapeutics
Chair, CEOsummit

Linda LeBeau, Silicon Valley Bank
Chair, Marketing Committee

Richard Mejia, Ernst & Young LLP
Chair, Annual Dinner Committee

Trindl Reeves, Marsh
Chair, Sponsorship Committee

Scott Rieger, Strategic Investor Relations Inc.
Chair, Annual Dinner Committee

Ted Roth, Alliance Pharmaceutical Corp.
Chair, CEOsummit

Annual Dinner Committee

Julie Ames, CancerVax Corporation
Meredith Dow, K-Force Scientific
Kim Anderson
Jeanine Jacobson, UCSD Athena
Mike Milligan, Barney & Barney LLC
Tom Murphy, R.J. Watkins & Company, Ltd.
Bernie Rhinerson, Southwest Strategies
Elaine Rosen, K-Force Scientific

Marketing Committee

Julie Ames, CancerVax Corporation
Mark J. Benedyk, Ph.D., FARMAL LLC
Carin Canale, Atkins + Associates
Theresa DeLeone, The T-Sector
Wendy Edwards, Elan Pharmaceuticals
Bonnie Feldman, Bio-Financial Consulting
Tara Hale, LMA North America
Fred Hill, Kymeric Consulting
Molly Ingraham, CHI
Craig Knox, Cooley Godward LLP
Andrea Lynn, Immusol
David Nelson, Ph.D., Anadys Pharmaceuticals
Colleen Peterson, Peterson/Hill Marketing
Marci Pozzi, Atkins + Associates
Mark Riley, Advanced Clinical Services
Wendy Smith, Heller Ehrman
Hillary Theakston, Diversa Corporation

Program Committee

Julie Ames, CancerVax Corporation
Anette Asher, UCSD CONNECT
Bryan Bjorndal, Genetronics, Inc.
Carin Canale, Atkins + Associates
Stephen Chang, Canji, Inc.
Brian Cunningham, Rigel Pharmaceuticals
Fred Cutler, UCSD CONNECT
Diana DeWalt, The HR Company
Anna Maria Frost-Jensen, 3 P Ventures
Jennifer Giottonini, Isis Pharmaceuticals
David Gollaher, CHI
Greg Horowitt, UCSD CONNECT
Martin Mattingly, Agouron Pharmaceuticals
Sean McCarthy, Structural GenomiX
Tari Park, Sun Microsystems
Bill Ralston
Wendy Smith, Heller Ehrman
Nandini Tandon, Ph.D., RBC Capital
Ken Widder, Santarus
Troy Wilson, Genomics Institute of the Novartis Research Foundation
Jerry Yakatan Ph.D., Avanir Pharmaceuticals

Sponsorship Committee

Terry Bruggeman
Dave Calendar, IBM
Laurent Fischer, MedVantx
Don Grimm
Brantley Haigh, Canadian Consulate General
Bruce Jenett, Heller Ehrman
Barbra Kosacz, Cooley Godward LLP
Chris Nolet, Ernst & Young LLP
Tim Scott, Pharmatek Laboratories, Inc.
Don Tucker, Accenture

BIOCOM Mission

BIOCOM

BIOCOM positions the Greater San Diego life science community for success on the world stage by positively influencing research, development and commercialization of innovative and effective products to improve human health and quality of life.

BIOCOM is actively engaged in ensuring that the life science industry remains a strong and growing part of the region's economy. The association is sanctioned by its members to facilitate public policy advocacy on a local, regional and statewide level, provide capital formation opportunities, promote the industry within the community, provide networking opportunities, organize meetings and conferences, provide professional development programs, communicate news and information and administrate member benefits such as the BIOCOM Purchasing Group.

San Diego Life Science

The San Diego life science community is dynamic and entrepreneurial! Highly concentrated and diverse, the region is one of the most prominent life science centers in the world. San Diego produces 9% of all sales and drug revenue in the United States with revenue at $874 million and research and development expenditures at $555 million. Among life science executives, San Diego quality of life is ranked number one and our workforce is ranked third nationwide. San Diego boasts the highest number of NIH grants per capita in the nation. Most importantly, San Diego has in residence, the highest number of science-based Nobel winners in the world.

Membership Information

BIOCOM invites you to learn more about the ways we can get you connected to our region's life science industry. If you would like more information on BIOCOM or the life sciences industry in San Diego please contact Jennifer Henry, Membership Manager, at (858) 455-0300.

CHI/CONNECT

UCSD CONNECT is the globally recognized, university-based public benefits organization fostering entrepreneurship in the San Diego region by catalyzing, accelerating, and supporting the growth of the most promising technology and life sciences businesses.

Founded in 1985 at the urging of San Diego's business community, UCSD CONNECT is widely regarded as the nation's most successful regional program linking high-technology and life science entrepreneurs with the resources they need for success: technology, money, markets, management, partners, and support services. Part of the University of California, San Diego (UCSD), CONNECT has a dual role in accelerating growth: it provides added value and delivers targeted, high-level expertise to San Diego's technology business community by teaming up with the region's most prominent industry-specific organizations and individuals, and by partnering with world-class UCSD resources, such as the School of Medicine, Jacobs School of Engineering, San Diego Super Computer Center, and Scripps and Salk Institutes.

CONNECT's services are tailored to meet the varying needs of San Diego entrepreneurs at all stages of their business life cycles and growth. Since its inception, CONNECT has assisted more than 800 technology companies. Its programs serve as a catalyst for the development and exchange of ideas, a forum to explore new business avenues and partnerships, and an opportunity to network with peers.

CONNECT is entirely self-supporting and receives no funding from the university or the state of California. It is supported through membership dues, course fees, and corporate underwriting for specific programs.

The California Healthcare Institute

The California Healthcare Institute (CHI) represents more than 225 leading biotechnology, medical device and pharmaceutical companies, as well as public and private academic research institutions in California. CHI's mission is to advance responsible public policies that foster medical innovation and promote scientific discovery. The Institute conducts economic and public policy research, produces industry analyses, develops educational programs, formulates policy, and engages in direct advocacy on behalf of California's biomedical R&D enterprise and the patient community it serves.

Ligand is an emerging specialty pharmaceutical company that discovers, develops and markets innovative small molecule drugs to address critical, unmet medical needs. Ligand markets four oncology and dermatology products in the United States. Ligand's fifth and newest product, AVINZA®, is a treatment for chronic, moderate-to-severe pain.

LIGAND®
PHARMACEUTICALS

www.ligand.com

MAXIM

PHARMACEUTICALS

Maxim is a global bio-pharmaceutical company with a diverse pipeline of product candidates for life-threatening cancers, hepatitis C and other chronic liver diseases.

8899 University Center Lane, Suite 400, San Diego, CA 92122
858-453-4040 www.maxim.com

Partners for Life.

Sun microsystems

At Sun Microsystems,™ we recognize that no company works alone in the life sciences community. That's why, as a leader in the field, we work with the foremost hardware and software vendors, systems integrators, standards bodies, academic organizations, and customers in developing solutions that deliver IT therapeutics for the global life science community.

www.sun.com/lifesciences